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Cardiovascular	disease	 (CVD)	 includes	all	diseases	 that	affect	 the	heart	and	blood	














	 Together	 with	 secondary	 complications	 after	 survival,	 CVD	 results	 in	 an	
enormous	burden	on	the	global	economy,	estimated	to	cost	the	European	Union	about	
196	billion	Euro10	and	the	United	States	about	396	billion	Euro1	annually.	This	clearly	




Observations	 of	 atherosclerosis	 date	 back	 as	 far	 as	 Aristoteles,	 who	 observed	
that	 arteries	 of	 young	 individuals	 were	 straight	 and	 open	 vessels,	 while	 arteries	
of	 older	 individuals	 were	 tortuous	 and	 narrowed	 vessels11.	 Initially	 the	 process	 of	
arterial	 stiffening	was	 seen	 as	 a	 result	 of	 aging	 and	 only	 in	 the	 19th century was 
the	process	acknowledged	as	pathogenic.	Early	work	by	Nikolai	Anichkov	determined	
the	role	of	cholesterol	in	the	development	of	atherosclerosis12.	Soon	after,	Virchow13,	






gruel-like)	 and	 “sclerotic”	 (hardening)	 aspect	 of	 the	 disease	 and	 has	 been	 used	











already	 indicates	 the	 difficulty	 of	 modulating	 the	 atherosclerotic	 disease	 process.	
Endothelial	dysfunction,	vascular	 inflammation,	and	 the	accumulation	of	 lipids	and	
fibrous	 elements	 within	 the	 vessel	 wall	 are	 all	 characteristic	 for	 atherosclerosis.	
Eventually	this	will	result	 in	 lesion	formation,	vascular	remodeling,	abnormal	blood	
flow,	stenosis,	and	possibly	thrombus/emboli	formation.
1.1 Initial Atherosclerotic Lesions
Atherosclerotic	 lesion	 development	 is	 closely	 linked	 to	 local	 hemodynamic	 factors.	
Dysfunction	of	 vascular	 endothelial	 cells	 (ECs)	preferentially	 occurs	 in	 areas,	 such	






	 LDL	 can	 passively	 diffuse	 through	 the	 disturbed	 EC	 layer	 and	 is	 retained	




nitric	 oxide	 synthase	 (iNOS)	 and	 NADPH	 oxidases	 that	 are	 found	 within	 lesions21.	
Oxidized	LDL	(oxLDL)	leads	to	the	activation	of	ECs,	which	increase	their	expression	
of	 adhesion	 molecules,	 cytokines,	 and	 growth	 factors	 (e.g.	 macrophage	 colony-
stimulating	 factor;	 M-CSF)22.	 These	 changes	 in	 the	 vascular	 environment	 result	
in	 an	 activation	 of	 resident	 lymphocytes,	 dendritic	 cells	 (DCs),	macrophages,	 and	
smooth	muscle	cells	(SMCs).	Moreover,	an	enhanced	recruitment	and	transmigration	
of	 leukocytes	 is	 mediated	 by	 three	 main	 chemokine	 receptor/chemokine	 pairs:	
CC	 chemokine	 receptor	 (CCR)	 2/	 CC	 chemokine	 ligand	 (CCL)	 2,	 CX3C-chemokine	
receptor	1	 (CX3CR1)/CX3CL1	and	CCR5/CCL523,24.	 This	 culminates	 in	a	 chronic	 low-
grade	inflammation	of	the	vessel	wall25.	Recruited	monocytes	are	exposed	to	growth	
factors	within	the	vessel	wall,	which	stimulate	their	differentiation	to	macrophages26.	
Moreover,	M-CSF	enhances	 the	expression	of	scavenger	 receptors	 in	macrophages,	
which	recognize	oxidation-specific	epitopes	and	thereby	enable	uptake	of	cell	debris	
and	oxLDL27.	By	accumulating	cholesterol	esters,	macrophages	transform	into	 lipid-
rich	 foam	 cells,	 so	 called	 due	 to	 cytoplasmic	 lipid	 droplets	 giving	 them	 a	 ‘foamy’	
appearance	under	electron	microscopy.	These	cells	are	one	of	the	most	characteristic	
features	 of	 the	 atherosclerotic	 lesion.	 Eventually	 cholesterol	 accumulation	 induces	
cytotoxicity,	 resulting	 in	 foam	cell	 apoptosis.	The	 lipid-rich	 remnants	of	 foam	cells	







pathogen-associated	molecular	 patterns	 (PAMPs)	 and	 danger-associated	molecular	










not	 occur	 and	 the	 inflammation	 advances,	 the	 immune	 response	will	 switch	 from	
a	protective	to	a	damaging	process.	The	amount	of	(activated)	 lesional	 leukocytes	
in	 early	 atherosclerosis	 steadily	 increases	 due	 to	 ongoing	 recruitment	 and	 further	
activation	of	the	cells	(Figure	1B).	This	results	in	a	vicious	progressive	inflammatory	
cycle	 and	 fatty	 streaks	 then	 become	more	 advanced	 atherosclerotic	 lesions,	 also	
called	‘fibrous	lesions’29.	
Figure 1. Initiation and Progression of Atherosclerosis. Atherosclerosis	 occurs	 at	 sites	 in	 the	
arterial	 tree	where	 laminar	flow	 is	disrupted.	A.	Atherogenic	 lipoproteins	such	LDLs	enter	 the	 intima,	
where	they	are	modified	and	aggregate	within	the	extracellular	intimal	space,	thereby	increasing	their	
phagocytosis	 by	macrophages.	Unregulated	uptake	of	 atherogenic	 lipoproteins	by	macrophages	 leads	
to	 the	 generation	 of	 foam	 cells.	 Foam	 cell	 accumulation	 leads	 to	 fatty	 streaks	 formation.	B.	 Smooth	
muscle	 cells	 secrete	 large	 amounts	 of	 extracellular-matrix	 components,	 such	 as	 collagen,	 increasing	
lesion	formation.	In	addition	to	monocytes,	other	types	of	leukocytes	are	recruited	and	help	to	perpetuate	
a	state	of	chronic	inflammation.	C.	Foam	cells	eventually	die,	resulting	in	the	release	of	cellular	debris	
and	 crystalline	 cholesterol,	 contributing	 to	 necrotic	 core	 formation.	 In	 addition,	 smooth	muscle	 cells	
form a fibrous	 cap.	 This	 non-obstructive	 lesion	 can	 rupture	 or	 the	 endothelium	 can	 erode,	 resulting	
















but	 after	 a	 critical	 point	 expands	 into	 the	 lumen.	 The	 fibrous	 lesions	 continue	 to	
expand	due	to	infiltration	(and	proliferation)	of	leukocytes,	continuous	production	of	
extracellular	matrix	and	accumulation	of	extracellular	lipids29.







rupture	 of	 the	 fibrous	 cap	 often	 occurs	 at	 the	 shoulder	 regions	where	monocytes	
enter	 and	 accumulate37.	 Degradation	 processes	 may	 be	 accompanied	 by	 the	
production	of	tissue	factor	by	macrophages,	which	can	accumulate	in	lesions.	Upon	
rupture,	this	thrombogenic	material	will	result	in	initiation	of	the	coagulation	cascade	
and	 thrombus	 formation	 (Figure	 1C).	 The	 thrombus	 can	 either	 cause	 blockage	 of	
that	 particular	 artery	 or	 it	 can	 travel	with	 the	 blood	 flow	and	 lead	 to	 blockage	 of	






to	correlate	with	 the	 type	of	angina	pectoris	 in	patients:	Unstable	angina	patients	
demonstrate	complex	lesions	and	thrombus	formation,	while	stable	angina	patients	
demonstrate	 more	 non-complex	 stable	 lesions38,39.	 Additionally,	 increased	 tissue	
factor	and	macrophage	content	have	been	associated	with	unstable	angina40.	Patients	












1.3 Experimental Models of Atherosclerosis
As	with	all	diseases,	preclinical	research	largely	depends	on	appropriate	in	vitro	and	
in	vivo	models	 for	predictions	of	 treatment	effectivity.	 In	vitro	modulation	of	 cells,	
either	cell	lines	or	primary	cultures,	can	identify	specific	responses	or	genes	involved	
in	 disease	 processes.	 Moreover,	 co-cultures	 of	 various	 cells	 can	 identify	 specific	









	 Animal	 models	 therefore	 still	 provide	 the	 best	 opportunity	 to	 evaluate	
complex	 interactions	 in	 atherosclerosis.	After	 initial	 in	 vitro	 testing,	 they	offer	 the	
best	opportunity	for	preclinical	screening	of	therapeutic	strategies.	Numerous	species	
have	been	used	to	 investigate	mechanisms	of	atherosclerosis,	such	as	non-human	
primates48,	 swines49,	 rabbits50,	 rats51	and	mice.	The	mouse	has	become	 the	model	
of	choice	for	atherosclerosis	research	for	simple	reasons:	they	are	easily	genetically	
modified,	easy	to	house	and	breed,	and	relatively	low	cost	to	purchase.	Several	mouse	
models	 for	 atherosclerosis	 have	 been	 developed	 as	 wild	 type	 mice	 are	 relatively	
resistant	 to	 atherosclerosis	 and	C57BL/6	mice	 only	 develop	 small	 fatty	 streak-like	
lesions	when	fed	a	high	cholesterol	diet52.	The	most	commonly	used	transgenic	strains	
to	study	atherosclerosis	are	the	ApoE-/-	mice	and	LDLr-/-	mice53.
	 Apolipoprotein	 E	 (ApoE)	 and	 the	 LDL	 receptor	 (LDLr)	 are	 both	 crucially	




circulation.	 Deficiencies	 in	 either	 ApoE	 or	 the	 LDLr	 thus	 result	 in	 an	 increase	 in	
cholesterol	 and	 triglyceride-rich	 lipoproteins	 in	 the	 circulation.	 In	 humans	 familial	
















2. The Immune System in Atherosclerosis
As	mentioned,	chronic	inflammatory	processes,	besides	dyslipidemia,		are	responsible	
for	 the	 atherosclerotic	 disease	 process.	 Early	 indications	 for	 this	 came	 from	 the	
observation	of	inflammatory	infiltrates	in	atherosclerotic	lesions59.	Moreover,	in	humans	
markers	of	inflammation,	e.g.	C-reactive	protein	(CRP),	have	been	found	to	correlate	































monocyte	 and	neutrophil	 numbers,	which	promotes	 atherosclerosis75.	 Acute	 tissue	
injury	after	MI	was	also	shown	to	induce	proliferation	and	mobilization	of	HSPCs76,77.	














or	 inflammation	where	 they	 can	 extravasate80.	 Originally,	 MSCs	were	 investigated	
for	their	ability	to	repair	injured	tissues,	e.g.	after	MI81,	but	recently	have	also	been	
investigated	 for	 their	 immunomodulatory	 capacities.	 Many	 elaborate	 studies	 have	
shown	that	MSCs	can	interfere	with	DC	and	T	cell	function	and	are	immunosuppressive78.	
Interestingly,	IFN-γ	enhances	the	immunosuppressive	capacities	of	MSCs82.	Preclinical	
studies	 have	 shown	 that	 MSCs	 can	 prevent	 allograft	 rejection83,84	 and	 alleviate	
autoimmune diseases85–87.	Moreover,	in	a	phase	II	clinical	trial,	it	was	found	that	MSCs	
can	reduce	graft-versus-host	disease88.	Overall,	MSC	treatment	has	been	established	

















6G-)	 consists	 of	 two	main	 subsets	 differentiated	 by	 their	 expression	 of	 Ly-6C.	 Ly-












level97.	 Chemokine	 deficiencies	 as	 well	 as	 monocyte	 deficiencies	 of	 chemokines	
receptors	reduce	lesional	monocyte	infiltration	and	lesion	sizes	in	murine	models	of	
atherosclerosis.
	 The	 importance	 of	 the	 CCL2-CCR2	 axis	 has	 been	 extensively	 investigated.	
Both	deficiencies	of	CCL2101	and	 its	 receptor	CCR2102	have	been	shown	to	strongly	
inhibit	 lesion	formation	in	murine	models	of	atherosclerosis,	as	a	result	of	reduced	




in	advanced	 lesions,	 in	 line	with	a	recent	study	suggesting	that	 lesion	progression	







their	 recruitment	 and	 accumulation	 in	 atherosclerotic	 lesions106.	 Additionally,	 gene	
therapy	by	transfection	of	an	N-terminal	deletion	mutant	of	the	human	CCL2	gene	
into	 the	 skeletal	 muscle	 significantly	 inhibited	 lesion	 formation	 in	 ApoE-/- mice107.	
Interestingly,	 while	 CCR2	 deficiency	 does	 not	 affect	 lesion	 progression,	 blockade	
of	 CCL2	 by	 this	 N-terminal	 deletion	mutant	 of	 the	 CCL2	 gene	was	 found	 to	 limit	
lesion	progression108.	In	humans	CCL2109,110	serum	levels	and	CCR2	on	monocytes110	





in	 the	 recruitment	 of	monocytes	 to	 atherosclerotic	 lesions	 in	 ApoE-/- mice112.	 Both	













interactions	 are	 needed	 for	 firm	 adhesion	 of	 rolling	monocytes123.	 However,	 while	












lesion	size	of	CCR5	antagonist-treated	CCL2-/-CX3CR1-/-ApoE-/-	mice is not due to an 
additional	reduction	in	Th1	recruitment.
	 In	 addition	 to	 the	 three	 main	 chemokines	 involved	 in	 recruitment	 of	




to	 the	vasculature131	 and	 their	 accumulation	 in	murine	atherosclerotic	 lesions132,133.	
Additionally	 CXCR2-/-LDLr-/-	 mice	 and	 CXCR1-/-LDLr-/-	 show	 reduced	 atherosclerotic	











macrophage	 numbers	 with	 altered	 functions	 and	 a	 dramatic	 86%	 reduction	 in	
atherosclerosis138.	 However,	 it	 should	 be	 noted	 that	 these	mice	 also	 already	 have	
reduced	monocytes.	The	same	accounts	for	studies	that	have	used	clodronate	liposomes.	
These	liposomes	deliver	clodronate	to	macrophages,	resulting	in	their	apoptotis.	This	








assessed	 by	 systemic	 administrations	 of	 tumor	 necrosis	 factor-related	 apoptosis-
inducing	 ligand	 (TRAIL),	which	only	 resulted	 in	 apoptosis	 of	macrophages	but	not	




it	 via	 scavenger	 receptors	 (SRs),	 including	 SR-A1142	 and	 CD36143,	 which	 together	
mediate	 up	 to	 90%	 of	 oxLDL	 uptake	 in	 vitro144.	 Eventually	macrophages	 undergo	










	 The	accumulation	of	 lipid	droplets	 in	macrophage	results	 in	a	shutdown	of	
endogenous	cholesterol	biosynthesis	and	LDLr	expression	by	inhibition	of	the	sterol	
regulatory	 element-binding	 protein	 (SREBP)	 pathway149.	 However,	 this	 does	 not	








and	 (3)	 fatty	 acid	 synthesis	 genes,	 promoting	 re-esterification	of	 cholesterol.	ABC	




acceptors.	ApoA-I	 is	 the	major	 apolipoprotein	 of	HDL	and	 is	 produced	 in	 the	 liver	
or	 intestine.	 ApoA-I	 can	 accept	 cholesterol	 esters	 from	 ABCA1,	 thereby	 forming	
nascent	HDL,	which	is	subsequently	converted	to	mature	HDL	by	esterification	of	free	
cholesterol	 by	 lecithin	 cholesterol	 acyltransferase	 (LCAT).	 Mature	 HDL	 can	 in	 turn	
accept	free	cholesterol	from	ABCG1	and	SR-BI28.	HDL	then	transports	the	cholesterol	













increased	 lesion	 formation154,	 or	 even	 decreased	 lesion	 development155,156 and 
progression157.	 Reduced	 atherosclerosis	 was	 attributed	 to	 increased	 macrophage	












while	LPL	has	beneficial	effects	 in	 the	periphery165,	 its	expression	 in	 lesions	seems	
pro-atherogenic	by	production	of	cholesterol	ester-rich	lipoproteins,	which	in	turn	can	
be	oxidized	and	taken	up	by	macrophages166.	
	 In	 addition	 to	 their	 role	 in	 local	 lipid	 metabolism	 in	 the	 arterial	 wall,	
macrophages	are	 involved	 in	modulating	 immune	responses.	They	express	several	
pattern	 recognition	 receptors	 (PRRs)	 by	 which	 they	 can	 sense	 PAMPs	 or	 DAMPs	







	 Macrophages	 are	 influenced	 by	 their	 microenvironment:	 inflammatory	
mediators	 and	 microbial	 products	 can	 modulate	 macrophage	 phenotype.	 Naïve	
macrophages	 (M0)	 are	 unpolarized	 macrophages	 generated	 by	 M-CSF,	 which	 can	
then	be	polarized	based	on	the	cues	from	their	environment.	However,	it	has	to	be	
acknowledged	that	macrophage	phenotypes	are	only	a	snap-shot	of	a	current	situation	
and	 are	 a	 simplification	 of	 a	 continuum	 of	 different	 functions	 that	 macrophages	
can	adopt.	 In	 fact,	macrophages	have	been	shown	to	be	able	 to	re-polarize	under	

























2.3.2 Alternatively Activated Macrophages (M2)
IL-4	polarizes	macrophages	 to	a	so-called	 “alternative”	 state	characterized	e.g.	by	
upregulation	of	the	mannose	receptor	(CD206)179.	These	macrophages	show	reduced	









inflammatory	 mediators,	 M2	 macrophages	 are	 thought	 to	 be	 anti-atherogenic.	




2.3.3 Mox, Mha and M4 Macrophages
As	 mentioned,	 the	 microenvironment	 is	 crucial	 in	 determining	 the	 macrophage	






in	 lesions,	 can	 influence	macrophage	phenotype.	Both	Mox	macrophages	 (induced	
by	 oxidized	 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine,	 OxPAPC171)	
and	Mha	macrophages	(resulting	from	intraplaque	haemorrhage182)	show	increased	
expression	of	heme	oxygenase-1	(HO-1),	vascular	endothelial	growth	factor	(VEGF)	
and	 IL-10.	 It	 is	 likely	 that	 these	macrophages	 function	 to	protect	other	 cells	 from	
Figure 2.  Different lesional macrophage phenotypes. Recruited	monocytes	 give	 rise	 to	 lesional	
macrophages.	As	a	result	of	environmental	factors	monocytes	differentiate	to	macrophages,	which	can	















disease	 process	 however	 still	 remains	 elusive.	 CXCL4,	 deposited	 by	 platelets	 onto	
the	inflamed	endothelium,	plays	a	role	in	recruiting	monocytes	to	the	atherosclerotic	
lesion183.	The	deficiency	of	CXCL4	has	been	found	to	result	in	reduced	atherosclerotic	




increased	 efflux,	 culminating	 in	 decreased	 foam	 cell	 formation.	 However,	 whether	
this	has	any	implications	for	atherosclerosis	has	yet	to	be	established186.	Mha	and	M4	
macrophage	phenotypes	are	specifically	defined	by	factors	in	the	microenvironment	
that	 induce	 distinct	 functions.	 However,	 if	 and	 to	 what	 extend	 they	 also	 show	
characteristics	of	M1	or	M2	macrophages,	and	could	thus	be	classified	as	specialized	
M1/M2	macrophages	remains	to	be	established.	
2.3.4 Regulatory Macrophages (Mregs) and Tumor-associated 
Macrophages (TAMs)
Several	 studies	 have	 described	 anti-inflammatory	macrophages,	 which	 have	 been	
termed	Mreg	or	TAM,	dependent	on	the	disease/mouse	model.	Mregs	have	been	shown	
to	be	induced	by	the	presence	of	immune	complexes	and	TLR	ligands	(similar	to	M2b	




allograft	 survival	 in	a	murine	heart	 transplantation	model188.	The	administration	of	

















	 As	 macrophages	 are	 increasingly	 found	 to	 show	 high	 functional	 diversity	
and	 plasticity,	 there	 is	 an	 increased	 need	 for	 experimental	 guidelines	 to	 establish	
specific	 phenotypes,	 and	 a	 nomenclature	 for	 macrophages.	 Murray	 et al.	 have	
recently	proposed	a	nomenclature	to	reduce	confusions	in	the	macrophage	field.	They	
recommend	 to	 define	macrophages	 by	 origin/source,	 activators,	 and	 a	 consensus	
collection	 of	 markers.	 For	 activated	 macrophages,	 they	 propose	 to	 indicate	 the	
activator	 in	parentheses,	e.g.	M(LPS+IFN-γ)	and	M(IL-4).	However,	 for	 the	 in	vivo	










	 cDCs	 can	 be	 further	 subdivided	 into	 migratory	 inflammatory	 DCs,	 which	
sample	the	periphery	and	migrate	to	lymph	nodes,	and	lymphoid	tissue-resident	DCs.	










	 Certain	 DCs	 in	 peripheral	 tissues,	 e.g.	 Langerhans	 cells	 in	 the	 skin	 and	
intestinal	 lamina	propria	DCs,	 can	be	derived	 from	monocytes.	Additionally,	 under	
inflammatory	 conditions,	 monocytes	 can	 differentiate	 into	 DCs.	 For	 example	
monocytes	can	differentiate	 into	Tip-DCs	(TNF-α/iNOS-producing	DCs)	which	show	
















2.4.1 DC presence in healthy and diseased aorta
In	the	vasculature,	DCs	are	found	to	localize	mostly	in	areas	of	the	aorta	susceptible	
to	 atherosclerosis204,205	 and	 their	 numbers	 increase	during	 lesion	development	and	
progression205,206.	Upon	atherosclerotic	 lesion	 formation,	 large	numbers	of	DCs	are	
found	within	atherosclerotic	lesions.	These	were	initially	identified	by	ultrastructural	







are	 distinct	 from	monocytes	 and	macrophages210.	 The	 precise	 contribution	 of	 DCs	
versus	macrophage	in	lesions	however	will	only	be	completely	understood	when	either	
exclusive	markers	or	a	panel	of	markers	for	these	cells	are	identified.	
	 In	atherosclerotic	 lesions,	DCs	 form	stable	contacts	with	T	cells,	mostly	 in	
the	 shoulder	 and	 rupture-prone	 regions212,	 indicating	 their	 crucial	 role	 in	 ongoing	
immune	responses.	Indeed,	DCs	present	in	murine	aortas	can	activate	T	cells208,213,214,	
suggesting	that	T	cell	activation	can	in	fact	directly	occur	within	the	atherosclerotic	
lesion.	 In	 line	 with	 this,	 DCs	 in	 advanced	 lesions	 were	 found	 to	 have	 a	 mature	





	 To	 establish	 the	 contribution	 of	 DCs	 to	 atherosclerosis,	 the	 CD11c-DTR	
LDLr-/-	mouse	model	was	used	to	deplete	DCs	and	a	55%	decrease	of	lesion	development	
was found209,216.	 Conversely,	 increased	 DC	 numbers	 due	 to	 an	 expanded	 lifespan	
of	 DCs	 (CD11c-specific	 expression	 of	 anti-apoptotic	 hBcl-2)	 resulted	 in	 increased	
numbers	of	Th1	and	Th17	cells,	and	increased	Th1-driven	IgG2c	autoantibodies,	while	
interestingly	lesion	size	was	not	affected216.	These	studies	indicate	a	pro-atherogenic	
role	 for	 DCs	 in	 atherosclerosis.	 However,	 it	 has	 to	 be	 noted	 that	 monocytes	 and	
macrophages	 also	 express	 CD11c	 under	 hypercholesterolemic	 conditions,	 making	

















of	 pro-inflammatory	 cytokines	 in	 other	 APCs219.	 As	 pDCs	 specifically	 express	 TLR7	
and	TLR9,	 they	are	equipped	 to	 recognize	nucleotides	or	DNA	 from	cellular	debris	
in	 lesions203.	 These	 studies	 suggest	 that	 different	 types	 of	DCs	 that	 control	 T	 cell	
homeostasis	exist	 in	atherosclerotic	 lesions	and	 that	while	 some	are	 resident	DCs,	
others	are	derived	from	recruited	monocytes.	
	 The	 accumulation	 of	moDCs	 in	 atherosclerotic	 lesions	 has	 been	 shown	 to	
critically	depend	on	CX3CR1221,	 indicating	a	possible	 role	 for	 Ly-6Clow monocytes in 










in	a	significant	 reduction	of	DCs	 in	 lesions	without	any	effects	on	other	monocyte-
derived	cells224.	A	future	challenge	will	be	to	decipher	the	relationship	of	various	DC	
phenotypes,	as	well	as	their	origin,	in	atherosclerotic	lesions	(Figure	3).



























for	the	 immune	system.	This	 is	 for	example	the	case	with	endogenous	heat	shock	
proteins	(HSPs),	which	resembles	HSP	expressed	by	pathogens	such	as	Chlamydia 
pneumonia and Helicobacter pylori230.	 Therefore,	under	 these	conditions,	DCs	may	














clearance	of	apoptotic	 cells.	This	process,	also	 termed	efferocytosis,	 is	enabled	by	
recognition	 of	molecules	 exposed	 on	 the	 cell	membrane	 of	 apoptotic	 cells.	 These	
so-called	‘eat-me-signals’	consist	of	modified	membrane	molecules,	such	as	altered	





Efferocytosis	 has	 been	 shown	 to	 be	 essential	 to	maintain	 homeostasis	 and	 when	
disrupted	 it	 can	 result	 in	 the	 onset	 of	 inflammation	 and	 autoimmunity,	 including	
atherosclerosis.	 In	 atherosclerosis,	 apoptotic	 foam	 cells	 should	 help	 to	 resolve	













Figure 4. Efferocytosis in early and advanced atherosclerotic lesions. A.	 Efficient	 efferocytosis	
in	early	atherosclerosis	results	in	a	rapid	clearance	of	apoptotic	macrophages	and	concomitant	release	

















2.4.3 DC maturation and immune responses in atherosclerosis
Immature	 DCs	 readily	 detect	 PAMPs	 of	microbes	 or	 DAMPs	 released	 by	 damaged	
cells	via	PRRs,	including	TLRs	and	cell	surface	C-type	lectin	receptors	(CLRs)236.	TLRs	
dimerize	and	undergo	 conformational	 changes	 that	enable	 them	 to	bind	Toll/IL-1R	
(TIR)-domain-containing	 adaptor	molecules.	 There	 are	 four	 adaptor	molecules,	 of	
which	 myeloid	 differentiation	 primary	 response	 gene	 (MyD)	 88	 and	 TIR-domain-





the	 context	 of	 atherosclerosis,	modified	 LDL	 can	 trigger	 TLR2	 and	 TLR4	 signaling	
through	CD36	and	result	in	activation	of	the	inflammasome238,239.	In	line,	TLR2	and	
TLR4	 deficient	 LDLr-/-	mice	 have	 been	 found	 to	 have	 reduced	 atherosclerosis240,241.	
In	 addition	 to	 these	 activation	 signals	 through	 PRRs,	 immature	 DCs	 can	 also	 be	
activated	through	pathogen-induced	non-specific	tissue	responses,	for	example	pro-
inflammatory	 cytokine	 production	 by	 ECs242.	 Furthermore,	 ECs	 and	 T	 lymphocytes	
can	also	contribute	to	DC	maturation	by	direct	cell-to-cell	contact	and	CD40-CD40L-
interaction,	 respectively195.	The	exact	maturation	signals	 for	DCs	 in	atherosclerotic	
lesions	remain	unknown,	but	likely	inflammatory	cytokines	and	cellular	debris,	such	
as	RNA	and	DNA	from	necrotic	cells,	activate	DCs.






















the	 immune	 response	 in	 atherosclerosis	 is	 directed	 towards	 components	 of	 native	
LDL247,	 suggesting	 that	 fully	 oxidized	 LDL	might	 not	 induce	 an	 immune	 response.	
MHCI	molecules	 acquire	 peptides	 from	 intracellular	 antigens,	which	 are	 generated	
by	proteasomal	processing,	in	the	endoplasmatic	reticulum;	while	MHCII	molecules	




in	mice	deficient	 in	the	 invariant	chain	CD74,	mediating	antigen	 loading	on	MHCII,	
which	show	decreased	atherosclerosis.	This	study	assessed	both	initial	and	advanced	

















lesion	 development258.	 The	 difference	 in	 the	 two	 studies	 assessing	 the	 effect	 of	
deficiency	of	CD80	and	CD86	could	be	due	to	the	experimental	setup	(bone	marrow	









a	 feasible	approach	 to	 reduce	atherosclerosis,	but	 that	specific	 “fine-tuning”	of	co-
stimulatory	signals	is	needed.
	 Antigen	recognition	as	well	as	co-stimulation	both	influence	T	helper	lineage	
commitment	 (Figure	 5),	 but	 cytokine	 production	 by	 DCs	 most	 potently	 shapes	 T	
cell	 responses263.	 Indeed,	we	 and	 others	 have	 shown	 that	 IL-12	 and	 IL-18	 play	 a	
crucial	role	in	atherosclerosis	development.	IL-12264	and	IL-18	deficiencies265	as	well	
as	 vaccination	 against	 IL-12266	 reduces	 atherosclerosis,	 while	 IL-12267	 and	 IL-18268	
injections	increase	atherosclerosis	burden.	Additionally,	DCs	can	express	a	variety	of	
chemokines,	e.g.	CCL17,	which	can	attract	T	cells	to	the	lesions213.
Figure 5. Immune responses in atherogenesis. OxLDL	 and	 coronary	 risk	 factors	 activate	 the	
endothelium	 and	 induce	 adhesion	 molecule	 expression.	 Monocytes	 migrate	 into	 the	 subendothelial	
space	using	adhesion	molecules,	differentiate	into	macrophages,	take	up	oxLDL,	and	become	foam	cells.	




molecule	 expression,	 and	 cytokine	 production	 by	 DCs.	 Tregs	 suppress	 effector	 T	 cell	 activation,	 the	
differentiation	of	naïve	T	cell	into	effector	T	cells.	Tolerogenic	DCs,	characterized	e.g.	by	downregulated	
expressions	of	CD80/CD86,	maintain	 the	 tolerance	 to	 self-antigens	by	 inducing	Tregs	or	by	 inhibiting	
effector	T	cells.	In	lesions	macrophages	and	DCs	release	cytokines	and	chemokines,	and	stimulate	the	
migration	 of	 smooth	 muscle	 cell	 (SMC)	 and	 other	 inflammatory	 reactions.	 Proatherogenic	 cytokines	








2.4.4 DC role in lipid metabolism in atherosclerosis
Besides	 their	 function	 as	 APCs,	 DCs	 also	 engulf	 lipids	 (via	 micropinocytosis,	
endocytosis,	scavenger	receptors,	and	efferocytosis)	and	form	foam	cells,	contributing	





enhanced	 antigen	 presentation	 to	 T	 cells	 and	 increased	 T	 cell	 proliferation245,270.	
On	 the	 other	 hand,	 it	 was	 found	 that	 uptake	 of	 oxidized	 phospholipids	 by	 DCs	
can	 impair	 maturation	 upon	 CD40	 and	 TLR2,	 TLR3	 and	 TLR4	 ligation271;	 possibly	
providing	a	control	for	excessive	DC	activation271.	Therefore,	it	will	be	interesting	to	
determine	 which	 components	 of	 oxLDL	 are	 responsible	 for	 both	 pro-inflammatory	
as	well	as	anti-inflammatory	responses	and	whether	these	responses	correlate	with	
macrophage	 function.	 As	 mentioned,	 in	 macrophages	 desmosterol	 was	 shown	 to	





	 Interestingly,	 a	 correlation	 between	 circulating	 cholesterol	 levels	 and	 DCs	
numbers	has	been	found.	DC-hBcl2	mice,	which	express	the	anti-apoptotic	Bcl-2	under	
the	CD11c	promoter,	have	highly	increased	numbers	of	DCs	as	well	as	significantly	
reduced	 plasma	 cholesterol	 levels216.	 Conversely,	 reduced	 levels	 of	 DCs	 in	 CD11c-
DTR	 ApoE-/-	mice	 results	 in	 enhanced	 systemic	 cholesterol	 levels216,	 while	 lesional	
lipid	accumulation	was	decreased209.	The	mechanisms	behind	this	effect	of	DCs	on	
cholesterol	metabolism	have	yet	to	be	identified.	








	 The	 crucial	 role	 of	 DCs	 in	 enhancing	 atherosclerosis	 was	 shown	 by	
adoptive	 transfer	 of	 malondialdehyde-modified	 LDL-pulsed	 DCs	 which	 aggravated	
atherosclerosis274.	This	indicated	that	adoptive	transfer	of	DCs	could	modulate	immune	
responses	in	atherosclerosis.	Indeed,	a	study	by	our	laboratory	showed	that	adoptive	






	 In	 the	 past	 two	 decades,	 the	 recognition	 of	 the	 crucial	 role	 of	 DCs	 in	
maintaining	steady	state	homeostasis	has	resulted	in	a	great	interest	for	DC	therapies	
for	autoimmune	diseases.	Initial	studies	showed	that	when	antigens	were	targeted	
to	 immature	 lymphoid	DCs	 in	 vivo	 this	would	 result	 in	 the	 generation	 of	 Tregs	 or	
T	cell	anergy276–279,	proving	the	potential	of	such	immature	antigen-presenting	DCs.	
The	 simple	 administration	 of	 immature	 DCs,	 however,	 harbors	 the	 danger	 of	 the	








the	 feasibility	 of	 biological	 factors	 (e.g.	 IL-10,	 1α,25-dihydroxyvitamin	 D3,	 TGF-β,	
M-CSF,	or	vasoactive	intestinal	peptide)	or	pharmacological	drugs	(e.g.	dexamethasone,	
aspirin	 or	 rapamycin)199,280.	 However,	 also	 pathogen-derived	 molecules,	 e.g.	 of	
C. albicans,	 or	 tumor-derived	molecules,	e.g.	mucins,	have	been	shown	 to	 induce	
Figure 6. Different approaches for DC-based vaccines in cancer that can be potentially 




with	an	activator	(or	inhibitor)	immune	responses	to	these	antigens	can	be	modulated. 4. Combination 












of	 DCs	 would	 also	 prevent	 them	 from	 maturing	 further	 in	 vivo.	 Several	 studies	
have	addressed	 this	possibility	by	 showing	 that	a	 semi-mature	DC	phenotype	 can	
be	 achieved,	 by	 e.g.	 TNF-α281,	 adrenomedullin282,	 and	 disruption	 of	 E-Cadherin	
clusters283.	 The	 latter	 mediate	 mainly	 cell-cell	 adhesions	 and	 likely	 disruption	 of	
these	by	mechanical	disruption	ensures	that	DCs	migrating	to	secondary	 lymphoid	
tissues	 under	 steady	 state	 induce	 tolerance.	 These	 semi-mature	 tolerogenic	 DCs	
have	a	marked	upregulation	of	co-stimulatory	molecules,	chemokines	receptors,	and	
antigen-presenting	molecules.	They	also	do	not	produce	pro-inflammatory	cytokines,	
but	anti-inflammatory	 cytokines	 such	as	 IL-10.	Moreover,	DCs,	which	are	exposed	
to	maturation	stimuli	such	as	LPS	for	a	prolonged	time	in	vitro	lose	their	capacity	to	
induce	Th1	responses.	Instead	they	produce	IL-10	and	induce	non-polarized	memory	
T	 cells	or	Th2	 responses284.	 Interestingly,	many	of	 the	 reagents	 found	 to	 induce	a	
tolerogenic	 phenotype	 are	 also	 produced	 under	 physiological	 conditions	 in	 tissues.	
They	could	provide	a	mechanism	whereby	spontaneously	maturing	DCs	are	prevented	
from	 inducing	 immune	 responses	 to	 self	 in	 vivo.	 Up	 till	 now,	 however,	 it	 remains	
unclear	 which	 exact	 signals	 are	 needed	 to	 promote	 and	maintain	 the	 tolerogenic	
phenotype	of	DCs.	
	 Different	 types	 of	 tolerogenic	 DCs	 have	 been	 shown	 in	 the	 past	 years	 to	
decrease	 ongoing	 immune	 responses	 in	 various	 autoimmune	 diseases281,285–287.	
Indeed,	Hermansson	et	al.	have	shown	that	tolerogenic	DCs	(ApoB100-pulsed)	can	









lesion	development,	 in	a	similar	manner	as	monocyte	recruitment290.	 It	was	 found	
that	T	cells	present	in	lesions	are	in	an	activated	state291,	with	more	than	60%	of	CD4+ 
T	cells	being	memory	T	cells292.	Recently,	increased	memory	CD4+	T	cells	and	reduced	








	 The	 overall	 role	 of	 T	 cells	was	 established	 in	murine	models	where	 T	 cell	
depletion	by	anti-CD3	treatment	resulted	in	a	reduction	of	initial	lesion	development295,	







2.5.1 Cytotoxic T cells
CD8+	 T	 cells	 (cytotoxic	 T	 cells)	 kill	 their	 targets	 by	 release	 of	 cytotoxins,	 such	 as	
granzymes	 and	 perforins,	 and	 expression	 of	 FasL.	 They	 have	 also	 been	 found	 to	
produce	large	amounts	of	IFN-γ	upon	activation,	such	as	in	atherosclerosis302.	Studies	
have	shown	a	correlation	between	CD8+	T	cells	and	coronary	heart	disease303,304 and 















T	cells	 likely	have	distinct	 functions	 in	atherosclerosis.	 It	 is	 therefore	of	significant	
interest	to	further	dissect	the	role	of	different	CD8+	T	cell	subsets	in	atherosclerosis.
2.5.2 Helper T cells
The	crucial	role	of	CD4+	T	cells	(T	helper	cells)	in	atherosclerosis	has	been	established	
in	several	mouse	models.	CD4+	T	cell	depletion	was	shown	to	reduce	lesions	by	70%	
in	C57BL/6	mice297.	Adoptive	 transfer	 of	CD4+	 T	 cells	 into	SCID	mice	dramatically	
increased	lesions	by	1.6-fold298.	Moreover,	MHCII	transgenic	mice	(expressing	other	







lesions	 can	 directly	modulate	 T	 cell	 function.	 Lysophosphatidylcholine,	 one	 of	 the	
main	 phospholipid	 components	 of	 oxLDL,	 can	 enhance	 the	 expression	 of	 CD40,	
CXCR4,	 and	 IFN-γ	 in	 human	 CD4+	 T	 cells,	 in	 the	 absence	 of	 APCs313.	 Moreover,	
increased	 membrane	 cholesterol	 was	 found	 to	 activate	 T	 cells,	 which	 were	 more	
prone	 to	 differentiate	 towards	 Th1	 cells314.	 It	 will	 be	 interesting	 to	 establish	 how	
hypercholesterolemia	 affects	 T	 cell	metabolism,	 and	 thereby	 T	 cell	 activation	 and	
proliferation.	T	cell	deficiencies	were	also	associated	with	a	significant	reduction	of	




















while	 IFN-γ	 injections	 result	 in	 a	 significant	 2-fold	 increase	 of	 atherosclerotic	
lesions322.	Additionally,	as	mentioned	previously,	IL-12	and	IL-18,	cytokines	involved	
in	Th1	generation,	are	also	crucially	involved	in	atherosclerosis264–268.	These	studies	
indicate	 that	 atherosclerosis	 is	 strongly	 driven	 by	 Th1	 cells	 and	 the	 production	 of	





progression316.	 When	 comparing	 atherosclerosis	 development	 in	 LDLr-/- mice on a 
C57BL/6	(Th1	dominated)	versus	BALB/c	(Th2	dominated)	background,	it	was	found	













	 IL-4	 administration	 or	 deficiency	 was	 found	 to	 have	 no	 effect	 on	 early	
atherosclerosis	in	ApoE-/- mice327.	While	IL-4	deficiency	in	LDLr-/-	mice	was	also	found	
to	have	no	effect	on	early	lesions	in	the	aortic	arch327,	the	same	group	showed	later	









protective	 IgM	antibodies,	 resulting	 in	 reduced	atherosclerosis61.	Recently	anti-IL-5	
autoantibodies	 have	 been	 shown	 to	 be	 associated	with	 human	 atherosclerosis,	 as	
antibody	 titers	 were	much	 higher	 in	 patients	 with	 coronary	 and	 peripheral	 artery	
disease	 than	 in	 controls,	 and	 additionally	 correlated	 with	 well-known	 risk	 factors,	
such	 as	 plasma	 LDL-cholesterol330.	 It	 was	 found	 that	 IL-33	 can	 specifically	 induce	
IL-5	 production	 in	 CD4+	 T	 cells331,332	 and	 that	 administration	 of	 IL-33	 reduces	
atherosclerosis	development	in	ApoE-/- mice332.	In	line	with	this,	anti-OX40L	treatment,	
which	results	 in	IL-5	producing	T	cells	(via	IL-33)	and	 increased	IgM	levels	results	
in	 reduced	 atherosclerotic	 lesion	 progression256.	 IL-13	 has	 also	 been	 shown	 to	
reduce	atherosclerotic	lesion	development	by	skewing	macrophages	towards	an	M2	
phenotype333.	
	 The	 different	 effects	 of	 IL-4,	 IL-5	 and	 IL-13	 on	 atherosclerosis	 indicate	
the	 difficulty	 of	 dissecting	 the	 role	 of	 Th2	 cells	 in	 atherosclerosis.	 This	 is	 further	
complicated	by	the	 fact	 that	 the	studied	cytokines	are	not	solely	produced	by	Th2	
cells	and	also	affect	other	cell	types.	Moreover,	innate	lymphoid	cells	have	also	been	














Th17	 cells	 in	 humans337.	 Th17	 cells	 produce	 IL-17A/F,	 IL-21	 and	 IL-22.	 The	 effect	
of	Th17	cells	 in	atherosclerosis	 remains	controversial.	T	cells	 isolated	 from	human	
atherosclerotic	coronary	arteries	were	found	to	produce	IFN-γ	as	well	as	IL-17	upon	















indicating	 a	protective	 role	 for	 Th17	 cells.	 Future	 studies	will	 have	 to	 resolve	 this	
issue;	again	T	cell	specific	knockout	models	should	prove	crucial	to	rule	out	the	effect	
of	other	immune	cells,	such	as	innate	lymphoid	cells,	NKT	cells,	NK	cells	and	γδ	T	cells.
2.5.2.4 Regulatory T cells
Regulatory	T	cells	(Tregs)	are,	as	the	name	suggests,	regulators	of	immune	responses	
and	 their	 main	 function	 is	 thought	 to	 be	 the	 inhibition	 of	 self-reactive	 T	 cells	 in	























roles	 in	 immune	 responses	 and	atherosclerosis.	Currently,	 the	distinction	between	
natural	Tregs	and	iTregs	can	only	be	derived	from	the	methylation	profile	of	the	FoxP3	
promoter356.
	 In	 addition	 to	 the	 distinction	 between	natural	 Tregs	 and	 iTregs,	 Tregs	 can	
be	 divided	 into	 central	 Tregs	 (patrolling	 characteristics),	 effector	 Treg	 populations	
(enhanced	function	due	to	recent	antigen	encounter,	present	in	lymphoid	organs)	and	
polarized	tissue-resident	Tregs	(present	in	non-lymphoid	organs)355.	Whether	these	
Treg	 populations	 derive	 from	 natural	 Tregs	 or	 iTregs	 is	 still	 unclear.	 Central	 Tregs	
can	specialize	into	effector	Tregs	and	specific	tissue-resident	Tregs.	It	appears	that	
TCR	ligation	and	IL-2	are	needed	for	this	differentiation	and	that	the	specific	tissue	
microenvironment	 is	 pivotal	 as	 well355.	 Recent	 studies	 indicate	 that	 transcription	
factors	specific	for	the	differentiation	of	CD4+	T	cells	result	 in	distinct	capacities	 in	
Tregs	to	inhibit	these	specific	T	helper	subunits,	thereby	matching	specific	Tregs	with	
their	 specific	 Th	 target	 cells.	 For	 example	 in	 response	 to	 IFN-γ,	 Tregs	 upregulate	
























and	 B	 cells366,367.	 Tregs	 were	 also	 found	 to	 suppress	 CCL2	 production,	 resulting	
in	 reduced	 recruitment	 of	 Ly-6Chi monocytes368.	 Tregs	 are	 capable	 of	 suppressing	
immune	responses	via	multiple	mechanisms	and	which	mechanism	is	predominant	
likely	depends	on	the	microenvironment	and	the	presence	of	antigens	and	APCs.
	 In	 atherosclerotic	 lesions,	 Tregs	 constitute	 about	 1-5%	 of	 all	 T	 cells326.	
Interestingly,	this	is	much	lower	than	in	other	inflammatory	diseases326.	Indeed,	low	
levels	of	Tregs	are	associated	with	increased	risk	for	MI369 and coronary syndromes370.	
During	murine	atherosclerosis	it	was	found	that	Treg	numbers	significantly	decrease	










CD80-/-CD86-/-	bone	marrow	showed	a	 significant	 reduction	of	 Tregs	and	 increased	
atherosclerotic	 lesions258.	 Also	 specific	 depletion	 of	 CD25-positive	 cells	 increased	
Figure 7. Regulatory T cells in atherosclerosis. Regulatory	T	cells	can	modulate	several	processes	
involved	 in	the	development	of	atherosclerosis.	Tregs	can	 inhibit	proatherogenic	T	cells,	DC	activation	
and	migration,	macrophage	inflammation,	foam	cell	formation,	endothelial	cell	(EC)	activation	and	can	
affect	 cholesterol	metabolism.	Reproduced	with	permission	 from	 the	Wolters	Kluwer	Health.	 Foks	AC,	




atherosclerotic	 lesion	development	 in	ApoE-/- mice258.	Reconstitution	of	LDLr-/- mice 
with	 bone	 marrow	 from	 depletion	 of	 regulatory	 T	 cell	 (DEREG)	 mice	 (expressing	
DTR	under	the	control	of	FoxP3)	and	depletion	of	Tregs	by	diphtheria	toxin	injection	
were	 found	 to	 significantly	 increase	 atherosclerotic	 lesions373,374.	 Interestingly	 also	
increased	VLDL	and	plasma	cholesterol	levels	were	found	in	these	mice	indicating	a	
link	between	Tregs	and	 cholesterol	 homeostasis374.	Our	 laboratory	has	 shown	 that	
vaccination	against	FoxP3,	resulting	in	the	depletion	of	Tregs,	significantly	increases	
atherosclerotic	 lesion	 development375.	 The	 opposite	 approach	 to	 increase	 Tregs	 by	











3. Outline of this Thesis 
Recent	years	have	clearly	shown	the	crucial	role	of	inflammatory	immune	responses	
in	 atherosclerotic	 lesion	 development.	 However,	 although	 our	 knowledge	 of	 how	
various	 immune	cells	contribute	to	the	disease	process	has	 increased	substantially,	
little	progress	has	been	made	in	finding	an	optimal	and	easily	translatable	immune	
cell-based	 therapy	 for	atherosclerosis.	 In	 this	book,	we	use	several	approaches	 to	
induce	tolerance	by	targeting	various	immune	cells,	of	which	some	resulted	in	effects	
on	lipid	metabolism	(Figure	8).
	 In	 chapter 2,	 we	 treated	 LDLr-/-	 mice	 with	 oxLDL-induced	 apoptotic	 DCs	
and	show	that	this	 is	a	novel	therapy	for	both	initial	and	advanced	atherosclerosis.	
This	 treatment	 results	 in	 induction	 of	 tolerogenic	 DCs,	 enhanced	 Treg	 numbers	
and	 reduced	 inflammatory	 monocyte	 responses.	 Earlier	 studies	 have	 shown	 that	
inhibition	of	efferocytosis	increases	atherosclerosis,	which	demonstrates	the	crucial	
































	 In	 chapter 5,	 we	 show	 that	 TLR2-mediated	 signaling	 is	 not	 all	 bad	 in	
atherosclerosis.	 We	 use	 the	 bacterial	 cell	 wall	 of	 S. aureus	 to	 induce	 TLR2/PI3K-
mediated	 IL-10	 responses	 in	 peritoneal	 macrophages	 and	 shift	 the	 macrophage	
phenotype	towards	an	M2b	phenotype.	These	cells	produce	strong	IL-10	responses	
















enhance	 anti-inflammatory	 cytokine	 production	 by	 macrophages,	 increase	 the	
presence	of	tolerogenic	DCs	and	increase	the	amount	of	Tregs.	Moreover,	we	show	
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tolerance	 induction	 to	 cleared	 antigens	 by	 DCs;	 however,	 this	 seems	 impaired	 in	
atherosclerosis	as	antigen-specific	tolerance	is	lacking.	This	could	partially	result	from	
a	reduced	emigration	of	DCs	from	atherosclerotic	lesions	due	to	the	high	cholesterol	





Methods and Results	 Adoptive	transfer	of	apopox-DCs	into	LDLr-/-	mice	either	before	
or	 during	Western-type	 diet	 resulted	 in	 increased	 numbers	 of	 CD103+	 tolerogenic	
splenic	DCs,	with	a	concomitant	increase	in	regulatory	T	cells.	Interestingly,	both	types	







decreases	 lesion	development,	 but	 only	 apopox-DCs	 can	positively	modulate	 lesion	












cells	migrate	to	 the	 lesions	and	exacerbate	 local	 inflammatory	responses.	In	more	




are	 crucially	 involved	 in	apoptotic	 cell	 clearance,	 termed	efferocytosis,	which	does	









In	 vivo,	 apoptotic	 cells	 have	 been	 shown	 to	 downregulate	 the	 immunostimulatory	
capacity	of	both	splenic	marginal	zone	macrophages	and	DCs12,13.

























injected	 intravenously	 to	enable	their	uptake	by	DCs	to	modulate	T	cell	 responses	
in	 developing	 and	 established	 atherosclerosis.	 We	 show	 here	 for	 the	 first	 time	


























Single	 cell	 suspensions	 of	 spleens	 from	 LDLr-/-	mice	were	 obtained	 by	 using	 a	 70	









OxLDL-Induced Apoptotic Dendritic Cells
2 
in	quintuplicates	in	96-well	round-bottom	plates	(Greiner	Bio-One)	in	the	presence	
or	 absence	 of	 αCD3,	 or	 αCD3	 and	 αCD28	 (2	 µg/mL,	 eBioscience)	 for	 72	 hours	 in	
complete	RPMI	1640,	supplemented	with	10%	FCS,	100	U/ml	penicillin/streptomycin,	
2mM	 L-glutamine	 (all	 obtained	 from	 PAA)	 and	 20	 μm	 β-mercaptoethanol	 (Sigma	
Aldrich).	Proliferation	was	measured	by	Ki-67	expression.	Relative	Ki-67	expression	
was	measured	by	flow	cytometry	and	is	expressed	as	mean	Ki-67%	with	stimulation	











At	 sacrifice,	 blood,	 spleen,	 bone	 marrow,	 and	 aorta	 were	 harvested.	 Single	 cell	








CD8-PerCP	 (BD	 Biosciences),	 CD11b-FITC,	 CD11c-APC,	 CD25-FITC,	 CD44-FITC,	
CD45-	 Pacific	 Blue,	 CD62L-Pacific	 Blue,	 CD103-FITC,	 FoxP3-APC,	 Gata-3-PE,	 Ki67-






To	 determine	 plaque	 size,	 10	 µm	 cryosections	 of	 the	 aortic	 root	 were	 stained	
with	 Oil-Red-O	 and	 haematoxylin	 (Sigma	 Aldrich).	 Corresponding	 sections	 were	
stained	 for	 collagen	 fibers	 using	 the	 Masson’s	 Trichrome	 staining	 (Sigma	 Aldrich)	
or	 immunohistochemically	 with	 antibodies	 against	 a	 macrophage	 specific	 antigen	
(MOMA-2,	 polyclonal	 rat	 IgG2b,	 1:1000,	 Serotec	 Ltd.).	 Goat	 anti-rat	 IgG	 alkaline	
phosphatase	 conjugate	 (dilution	 1:100;	 Sigma	 Aldrich)	 was	 used	 as	 a	 secondary	
















system	 (Applied	 Biosystems)	 using	 SYBR	 Green	 technology.	 The	 expression	 was	
determined	 relative	 to	 the	 average	 expression	 of	 three	 household	 genes:	 acidic	
ribosomal	 phosphoprotein	 PO	 (36B4),	 hypoxanthine	 phosphoribosyltransferase	
(HPRT),	and	60S	ribosomal	protein	L27	(Rpl27).	For	used	primer	pairs	refer	to	Table	1.
Cytokine and nitrite analysis
IL-10,	 TNF-α,	 IL-6	 (BD	 Biosciences),	 and	 CCL2	 (eBioscience)	 were	 determined	 by	






serum;	 Roche	 Diagnostics)	 was	 used	 as	 internal	 standard.	 The	 distribution	 of	
cholesterol	over	the	different	lipoproteins	in	serum	was	determined	by	fractionation	
of	30	µl	of	serum	of	each	mouse	using	a	Superose	6	column	(3.2	x	300	mm,	Smart-
System;	 Pharmacia).	 Total	 cholesterol	 content	 of	 the	 effluent	 was	 determined	 as	
described	above.















way	 ANOVA	 and	 data	 of	 two	 or	 more	 groups	 with	 more	 than	 one	 variable	 were	









late	 apoptosis	 in	 97%	 of	 the	 DCs.	We	 therefore	 chose	 this	 condition	 to	 generate	
oxLDL-induced	apoptotic	DCs	(apopox-DCs)	for	further	experiments.	As	a	control,	we	
generated	 apoptotic	 DCs	 by	 exposure	 to	 0.1	 μM	 epoxomicin	 (apopctrl-DCs),	 which	
induced	late	apoptosis	in	95%	of	DCs	(Figure	1).












control medium oxLDL epoxomicin
early apoptosis
late apoptosis



































viable	 responder	 DCs	 (respDCs),	 we	 added	 different	 amounts	 of	 apopox-DCs	 and	
apopctrl-DCs	 to	 immature	 respDCs	 for	24	hours	and	 subsequently	 stimulated	 them	
with	100	ng/mL	LPS	for	another	24	hours.	Both	apopox-DCs	and	apopctrl-DCs	decreased	
the	 release	 of	 inflammatory	 cytokines	 from	 respDCs:	 Pre-exposure	 to	 apopox-DCs	
resulted	in	a	significant	decrease	of	40%	in	IL-6	and	80%	in	TNF-α	responses,	while	
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We	 found	 that	apopox-DCs	potently	 induced	expression	of	ABCA1	and	ABCG1,	 two	
main	target	genes	of	liver	X	receptor	(LXR).	In	addition	to	an	upregulation	of	IL-10	
































































































inhibitory	molecule	 PD-L1,	 indicating	 a	more	 potent	 anti-inflammatory	 capacity	 of	
apopox-DC-exposed	DCs	(Figure	4).
OxLDL-presence in apoptotic DCs is needed to induce tolerogenic DCs and 
Treg responses in vivo
To	 assess	 whether	 apopox-DC	 treatment	 is	 beneficial	 for	 atherosclerosis,	 we	
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As	 splenic	 DCs	 efficiently	 clear	 apoptotic	 cells	 from	 the	 circulation13,	 we	 analyzed	
these	splenic	DCs	one	week	after	apoptotic	DC	treatment.	While	absolute	DC	numbers	
remained	 unchanged,	 myeloid	 immunogenic	 CD8α-CD11b+	 DCs	 were	 significantly	
decreased	by	10%	and	12%	in	apopox-DC-	and	apopctrl-DC-treated	mice,	respectively.	
No	 significant	 changes	 in	 lymphoid	 tolerogenic	 CD8α+CD11b-	DCs	 were	 observed.	
Interestingly,	a	significant	50%	increase	in	anti-atherogenic	CD103+CD11b-DCs	was	






































































































































































































































Tregs	 in	 the	 circulation.	 A	 significant	 24%	 increase	 was	 observed	 one	 week	 after	
apopox-DC	 treatment	 and	 remained	mildly	 increased	 (10%,	 n.s.)	nine weeks after 
treatment	 (Figure	7A).	A	similar	pattern	was	observed	 in	 the	spleen,	where	Tregs	
were	 robustly	 induced	 after	 one	week	 (35%)	and	 remained	mildly	 increased	 (9%,	
n.s.)	nine	weeks	after	 apopox-DC	 treatment	 (Figure	7B	and	data	not	 shown).	One	




However,	 this	 appeared	 to	 be	 related	 to	 an	 overall	 decrease	 of	 CD4+	 T	 cells	 and	
reduced	subsets,	resulting	in	an	increased	Treg	percentage	as	absolute	Treg	numbers	
in	the	spleen	were	not	changed	and	significantly	less	than	in	apopox-DC-treated	mice	































































































































































































































OxLDL-presence in apoptotic DCs enhances beneficial effects on monocytes 
Interestingly,	while	we	aimed	to	modify	DCs	and	subsequent	T	cell	responses,	major	
effects	 on	 circulating	 monocytes	 were	 observed	 by	 the	 apoptotic	 DC	 treatments.	
One	 week	 after	 treatment,	 a	 significant	 40%	 and	 36%	 reduction	 in	 circulating	
inflammatory	 Ly-6Chi	monocytes	 in	 apopox-DC-treated	 and	apopctrl-DC-treated	mice	
was	determined,	respectively.	In	the	apopox-DC-treated	mice	also	CCR2	expression	










Figure 8. Apoptotic DC treatment reduces monocyte responses in initial atherosclerosis. A. 
Apoptotic	DC-treatment	reduces	circulating	 inflammatory	monocytes.	After	one	week	and	nine	weeks	

































































































































































































































































Figure 9. Apoptotic DC treatment reduces initial lesion development. 
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OxLDL-presence in apoptotic DCs reduces inflammatory responses in 
established atherosclerosis
As	the	apoptotic	DC	treatment	proved	highly	effective	in	reducing	initial	atherosclerosis,	
we	 next	 determined	 whether	 it	 could	 reduce	 inflammation	 in	 pre-established	




earlier	 observations,	 apopox-DC	 treatment	 was	 effective	 in	 modifying	 splenic	 DCs	




increase	 in	 circulating	 Tregs	 in	 apopox-DC-treated	mice	 one	 week	 after	 treatment	
(Figure	10B).	
	 Interestingly,	 again	 only	 the	 apopox-DC-treatment	 resulted	 in	 a	 35%	
reduction	in	monocytes	and	a	19%	reduction	in	Ly-6Chi	monocytes nine weeks after 
treatment.	 In	 line	 with	 earlier	 observations,	 a	 significant	 41%	 decrease	 in	 CCL2	
serum	concentrations	in	apopox-DC-treated	mice	was	observed.	No	significant	effects	
of	 apopctrl-DC	 treatment	 on	 immune	 responses	 in	 established	atherosclerosis	were	
found	(Figure	10C).	
OxLDL-presence in apoptotic DCs is needed for stabilization and reduction of 
lesion progression 
Nine	weeks	after	the	last	treatment,	lesion	sizes	were	compared	to	the	baseline	group,	
which	was	 sacrificed	at	 the	 time	of	 apoptotic	DC	 treatment.	Atherosclerotic	 lesion	
progression	in	the	aortic	root	was	significantly	attenuated	by	38%	in	apopox-DC-treated	
Figure 10. Apopox-DC treatment reduces inflammation in established atherosclerosis. A. The	
effect	of	apoptotic	DC-treatment	on	splenic	DC	phenotype.	The	percentage	of	myeloid	CD8α-CD11b+DCs,	



























































































































































Figure 11. Apopox-DC-treatment reduces lesion progression and increases stability. A. At 
sacrifice,	 lesion	 size	 in	 the	 three	valve	area	of	 the	aortic	 root	was	determined;	 representative	 cross-
sections	 stained	with	Oil-Red-O	and	hematoxylin	 are	 shown.	B. Collagen	 content	was	determined	by	
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Discussion
Tolerogenic	 DC	 therapies	 have	 been	 investigated	 in	 autoimmune	 diseases	 for	
their	 potential	 to	 induce	 tolerance.	 In	 atherosclerosis,	 a	 study	 by	 Hermansson	 et 
al.	demonstrated	 that	adoptive	 transfer	of	apoB100-pulsed	 tolerogenic	DCs,	which	
induced	Treg	responses	in	vitro,	could	attenuate	lesion	development,	by	reducing	CD4+ 
T	cell	responses	in	vivo29.	In	this	study	we	show	that	apoptotic	DCs	and	in	particular	

















lesions	 was	 assessed.	 In	 both	 initiation	 and	 progression	 of	 atherosclerosis,	 only	












	 Interestingly,	 apopox-DC-treatment	 affected	 both	 monocyte	 counts	 and	
inflammatory	 monocytes	 in	 initial	 and	 advanced	 atherosclerosis,	 while	 treatment	
with	 apopctrl-DCs	 only	 affected	 inflammatory	 monocytes	 in	 initial	 atherosclerosis.	
One	week	after	treatment,	Ly-6Chi	monocytes	were	reduced,	which	was	in	line	with	

















Ly-6C	expression.	 Indeed,	our	 lab	 shows	 that	monocytes	 co-cultured	 in	 vitro	with	
apoptotic	DCs	downregulate	Ly-6C	(V.	Frodermann	and	J.	Kuiper,	unpublished	data).	
This,	however,	does	not	explain	long-term	effects	on	monocytes	in	apopox-DC-treated	
mice.	Swirski	et al.34 and	Tsou	et al.35	previously	described	the	critical	role	of	Ly-6Chi 
and	 CCR2+	 monocytes	 in	 atherosclerosis	 and	 their	 direct	 correlation	 with	 lesional	
macrophages.	They	show	that	the	inflammatory	environment	prevents	the	production	






to	 reduce	 initial	 lesion	 sizes	 in	 both	 apoptotic-DC-treated	 groups,	which	 is	 in	 line	
with	 reduced	 lesions	 in	 CCL2-/-	and	 CCR2-/- mice36,37.	 Apopctrl-DC	 treatment	 did	 not	
affect	monocyte	homeostasis	in	advanced	atherosclerosis,	again	indicating	that	the	
presence	of	oxLDL	 is	 required	 to	potentiate	 the	effect	on	monocytes	and	 to	affect	
them	in	the	advanced	stages	of	disease.





our	group	showing	that	CCR2	deficiency	does	not	affect	established	lesions38 and a 
recent	study	showing	that	macrophage	content	of	established	lesions	is	determined	
by	local	macrophage	proliferation	rather	than	influx	of	monocytes39.	The	pronounced	
effects	 of	 apopox-DCs	 on	 T	 cell	 responses	 and	 inflammation	most	 likely	 contribute	
to	the	clear	beneficial	effects	on	pre-established	lesions.	Only	apopox-DC-treatment	
increased	lesion	stability.	This	treatment	induced	an	increased	production	of	IL-10	by	















ABCG1,	 two	 target	 genes	 of	 LXR,	 than	 exposure	 to	 apopctrl-DCs.	 The	 activation	 of	
LXR	has	been	shown	to	induce	a	tolerogenic	phenotype	in	DCs,	with	decreased	pro-




DCs.	 In	addition	 to	 the	 increased	IL-10	production	by	apopox-DC-exposed	DCs,	we	
also	observed	an	upregulation	of	PD-L1	on	these	DCs.	PD-L1	was	shown	to	promote	
Treg	 development	 and	 maintenance47	 and	 this	 could	 contribute	 to	 the	 observed	
induction	of	Tregs	preferentially	by	apopox-DC-treatment.	Therefore,	overall	enhanced	
LXR	 activation	 through	 excess	 cholesterol	 might	 contribute	 to	 the	 enhanced	 anti-
inflammatory	effect	of	oxLDL-induced	apoptotic	DCs.
	 Apoptotic	 cell	 treatment	 was	 shown	 to	 be	 effective	 and	 safe	 in	 patients.	
In	 graft-versus-host	 disease,	 extracorporeal	 photopheresis	 has	 been	 employed	 to	
reduce	 immune	 responses.	 Up	 to	 10%	 of	 the	 patient’s	 circulating	 leukocytes	 are	
irradiated,	resulting	in	apoptosis,	and	re-infused,	which	leads	to	Treg	induction	and	
disease	amelioration,	without	 inducing	generalized	 immunosuppression48.	Moreover,	
a	 recent	 phase	 I	 clinical	 trial	 in	multiple	 sclerosis	 patients	 showed	 that	 treatment	
with	 myelin	 peptide	 cross-linked	 apoptotic	 splenocytes	 decreases	 antigen-specific	
T	 cell	 responses49.	 For	 atherosclerosis,	 we	 prove	 in	 this	 study	 that	 apoptotic	 DC	
treatment	 can	 significantly	 reduce	 lesion	 development,	 but	 that	 the	 presence	 of	
oxLDL	 in	apoptotic	DCs	 is	needed	 to	make	 them	potent	modulators	of	established	
atherosclerosis.	 Treatment	 with	 oxLDL-induced	 apoptotic	 DCs	would	 offer	 a	major	
advantage:	LDL	can	be	 isolated	 from	the	patients,	oxidized,	and	added	 to	patient-
derived	DCs,	providing	tolerance	induction	by	patient-specific	LDL-derived	peptides.	
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Objective	 A	 driving	 force	 behind	 atherosclerotic	 disease	 is	 the	 chronic	





Methods and Results	 CD11c-βcatEX3	DCs	possess	similar	antigen	uptake	capacities,	
but	displayed	enhanced	CD40,	CD86	and	CCR7	expression	and	reduced	production	
of	 pro-inflammatory	 cytokines	 TNF-α	 and	 IL-6	 upon	 LPS	 exposure.	 Consequently,	
CD11c-βcatEX3	DCs	inhibited	T	cell	responses	by	90%	as	a	result	of	a	33%	increased	
regulatory	T	cell	(Treg)	response.	




reduction,	 respectively).	 Additionally,	 CD11c-βcatEX3/LDLr-/-	 chimeras	 had	 reduced	
necrotic	cores	and	more	stable	collagen-rich	lesions,	while	this	was	not	observed	after	














in	human	atherosclerotic	 lesions.	DCs	 in	 the	 lesions	were	 found	 in	close	proximity	
to	 other	 leukocytes,	 already	 indicating	 their	 role	 in	 ongoing	 inflammation1.	During	















	 Due	 to	 their	 critical	 role	 in	 initiating	 adaptive	 immune	 responses,	we	 and	
others	 have	 addressed	 the	 possibility	 to	modulate	DCs	 in	 their	 capacity	 to	 induce	
T	 cell	 responses	 as	 a	 treatment	 option	 for	 atherosclerosis.	 Blocking	 antibodies	 for	
several	co-stimulatory	molecules	were	able	to	modulate	T	cell	responses	and	reduce	
atherosclerosis13,14.	 Additionally	 we	 have	 shown	 that	 adoptive	 transfer	 of	 oxLDL-
pulsed	mature	DCs	 reduces	 atherosclerosis	 by	 inducing	oxLDL-specific	 antibodies15 
and	 that	 oxLDL-induced	 apoptotic	 DCs	 also	 reduce	 atherosclerosis	 by	 inducing	









phenotype	 in	DCs	by	culturing	DCs	with	 immunosuppressive	components	 including	
cytokines18,	estriol19,	1α,25-dihydroxyvitamin	D320,	or	vasoactive	intestinal	peptide21.	
Interestingly,	many	of	these	factors	are	also	produced	in	tissues	under	physiological	
conditions.	 Nonetheless,	 it	 remains	 unclear	 which	 exact	 intracellular	 signals	 are	
needed	to	promote	and	maintain	the	tolerogenic	phenotype	of	DCs.








these	 tolerogenic	 DCs	 were	 able	 to	 induce	 peripheral	 tolerance	 and	 protect	 from	
experimental	autoimmune	encephalomyelitis24.	Interestingly,	β-catenin	was	also	found	
to	be	crucially	involved	in	maintaining	the	tolerogenic	phenotype	of	intestinal	DCs	and	




	 In	 this	 study,	 we	 explored	 the	 potential	 of	 inducing	 tolerogenic	 DCs,	 by	










LDLr-/-	 mice	 were	 originally	 obtained	 from	 The	 Jackson	 Laboratory	 and	 housed	
and	bred	at	 the	animal	 facility	of	 the	Gorlaeus	Laboratories.	Bone	marrow	donors,	
CD11c-βcatEX3	 and	 control	 non-transgenic	 littermates,	were	generated	by	breeding	
β-catEX3	fl/fl	 mice,	 carrying	 homozygous	 loxP	 site	 insertion	 flanking	 exon	 3	 of	
β-catenin	gene,	with	CD11c-Cre	 transgenic	mice	on	 the	C57BL/6	background.	The	





























Isolation, Loading and Stimulation of BM-derived and splenic DCs
DCs	were	cultured	as	previously	described15.	Briefly,	bone	marrow	cells	were	isolated	





colony-stimulating	 factor	 (GM-CSF).	DC	purity	was	 assessed	by	CD11c	 expression	
(flow	cytometry)	and	routinely	found	to	be	above	95%.
	 For	in	vitro	DC	cultures,	2	x	106	DCs	were	plated	in	2	cm	non-tissue	culture	
treated	 petri	 dishes	 (Greiner	 Bio-One)	 to	 determine	 cytokine	 responses	 and	 flow	
cytometry	analysis	upon	indicated	amounts	of	LPS	and	for	antigen	uptake	assessment.	







IL-6,	 TNF-α	 (all	 eBiosciences)	 and	 IL-10	 (BD	 Biosciences)	 were	 measured	 in	 the	
supernatants	of	LPS-stimulated	DCs	by	ELISA,	according	to	manufacturer’s	protocol.	
	 For	isolation	of	splenic	DCs,	spleens	were	harvested	after	sacrifice	and	DCs	
were	 isolated	 with	 a	 Dendritic	 Cell	 Enrichment	 Set,	 according	 to	 manufacturer’s	
protocol	(BD	Biosciences).
Proliferation assay and co-culture
For	DC-T	cell	co-cultures	(n=3	per	group),	0.5	x	105	DCs/well	were	cultured	with	2	x	
105	T	cells/well	(1:5)	in	triplicate	in	96-well	round-bottom	plates	(Greiner	Bio-One).	
CD4+	 T	 cells	 were	 isolated	 from	 a	 hyperlipidemic	 non-transplanted	 LDLr-/-	mouse 
with	 a	 CD4+	 T	 Lymphocyte	 Enrichment	 Set,	 according	 to	 manufacturer’s	 protocol	
(BD	Biosciences).	For	splenocyte	proliferation	(n=6	per	group),	2	x	105	splenocytes/	




eBioscience)	 for	 72	 hours	 in	 complete	 RPMI	 1640,	 supplemented	 with	 10%	 FCS,	
100	 U/ml	 penicillin/streptomycin,	 2mM	 glutamax	 (all	 obtained	 from	 PAA)	 and	 20	
μm	β-mercaptoethanol	 (Sigma-Aldrich).	 Proliferation	 of	 splenocytes	was	measured	
by addition of 3H-thymidine	 (0.5	 μCi/well,	 Amersham	Biosciences)	 for	 the	 last	 16	
hours	of	culture.	The	amount	of	 3H-thymidine	 incorporation	was	measured	using	a	
liquid	 scintillation	 analyzer	 (Tri-Carb	 2900R)	 as	 the	 number	 of	 disintegrations	 per	
minute	(dpm).	Responses	are	expressed	as:	stimulation	index	(SI)	=	mean	dpm	of	
quintuplicate	cultures	with	stimulation/	mean	dpm	of	quintuplicate	cultures	without	










PE	 (eBioscience,	 FJK-16s),	 T-bet-eFluor	 660	 (eBioscience,	 eBio4B10),	 IL-10-APC	
(eBioscience,	 JES5-16E3),	 IL-12p40	 (eBioscience,	 C17.8),	 CD86-APC	 (eBioscience,	
GL1),	 CD40-FITC	 (eBioscience,	 HM40-3),	 MHCII-FITC	 (eBioscience,	 M5/114.15.2),	







isothiocyanate	 (GTC)	method	 according	 to	 Chomczynski	 and	 Sacchi30 and reverse 
transcribed	 using	 RevertAid	 M-MuLV	 reverse	 transcriptase.	 Quantitative	 gene	
expression	analysis	was	performed	on	a	7500	Fast	Real-Time	PCR	system	(Applied	
Biosystems)	using	SYBR	green	technology	(Eurogentec).	Ribosomal	phosphoprotein	













stained	 with	 Oil-Red-O	 and	 hematoxylin	 (Sigma-Aldrich).	 Corresponding	 sections	
were	stained	for	collagen	fibers	using	the	Masson’s	Trichrome	method	(Sigma-Aldrich)	
or	 immunohistochemically	 with	 antibodies	 against	 a	 macrophage	 specific	 antigen	
(MOMA-2,	polyclonal	rat	IgG2b,	diluted	1:1000,	Serotec).	Goat	anti-rat	IgG	alkaline	
phosphatase	 conjugate	 (dilution	 1:100,	 Sigma-Aldrich)	 was	 used	 as	 a	 secondary	
antibody	 and	 nitro	 blue	 tetrazolium	 and	 5-bromo-4-chloro-3-indolyl	 phosphate	
(Dako)	as	enzyme	substrates.	To	determine	the	number	of	adventitial	T	cells,	CD3	
staining	was	performed	using	anti-mouse	CD3	(clone	SP7,	1:150,	ThermoScientific).	








Table 1. Primer Pairs. The	expression	of	genes	was	determined	relative	to	the	average	expression	of	



























CD11c-βcatEX3 DCs are tolerogenic and induce Tregs in vitro
To	determine	the	effect	of	β-catenin	stabilization	on	DC	phenotype	and	function,	we	





















































































































































































































































We	confirmed	 the	stabilization	of	β-catenin	 in	CD11c+	 cells	by	flow	cytometry	and	
found	a	highly	 significant	 overexpression	of	 β-catenin	when	pre-gating	on	CD11c+ 
cells	in	the	blood,	draining	lymph	nodes	of	the	heart	(hLNs),	and	spleen,	confirming	
the	stabilization	of	β-catenin	in	CD11c-βcatEX3	mice	(Figure	2).
Figure 2. CD11c-βcatEX3 mice show increased β-catenin stabilization in CD11c+ cells. LDLr-/-	mice 
reconstituted	with	either	bone	marrow	from	non-transgenic	 littermates	(control,	n=11)	or	from	CD11c-













































in	 aortic	 root	 lesion	 size	 of	 26%	 in	 CD11c-βcatEX3	mice	 compared	 to	 control	mice	
(control:	5.2	x	105	±	0.3	x	105	µm	versus	CD11c-βcatEX3:	3.8	x	105	±	0.5	x	105	µm;	



































































































Figure 3. CD11c-βcatEX3 mice show reduced lesion formation, increased stability and reduced 
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The	reduction	in	lesion	size	was	not	due	to	differences	in	body	weight	or	due	to	effects	
on	 lipid	 metabolism	 as	 total	 serum	 cholesterol	 levels	 and	 cholesterol	 distribution	
between	the	different	lipoprotein	fractions	was	not	different	between	the	groups	(data	
not	shown).












CD11c-βcatEX3 chimeras show decreased absolute CD4+ T cell numbers and 








































































































































the	CD11c-βcatEX3	mice.	 In	parallel,	a	62%	 increase	of	 circulating	Tregs	 in	CD11c-
βcatEX3	mice	was	seen,	which	likely	is	associated	to	the	more	tolerogenic	phenotype	of	
DCs	in	these	mice	(Figure	5A).	After	eight	weeks	of	WTD,	a	significant	50%	reduction	
of	CD4+	T	cells	 in	 the	circulation	(Figure	5A),	a	significant	17%	reduction	of	CD4+ 







complete	 inhibition	 of	 T	 cell	 differentiation	 to	 Th1	 in	 CD11c-βcatEX3	 mice	 (Figure	
5D).	This	indicated	that	DCs	present	in	the	spleen	were	still	able	to	modulate	T	cell	
responses	and	 induce	Tregs.	The	presence	of	Tregs	resulted	 in	a	60%	reduction	of	
proliferation	 of	 splenic	 CD11c-βcatEX3	 T	 cells	 compared	 to	 the	 control	 (Figure	 5E).	
This	was	 in	 line	with	reduced	CD4+	T	cell	numbers	observed	 in	the	spleen	 in	vivo,	
while	likely	Tregs	migrate	out	of	the	spleen	and	are	therefore	not	locally	increased.	
Moreover,	we	found	a	significant	58%	reduction	in	IL-6	production	and	a	non-significant	
Figure 5. CD11c-βcatEX3 mice show decreased CD4+ T cell responses and increased Treg 
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64%	reduction	of	TNF-α	production	by	splenocytes	(Figure	5F),	indicating	an	overall	
reduced	 inflammatory	 response.	 This	 is	 in	 line	with	 the	 reduced	pro-inflammatory	
cytokine	expression	observed	in	isolated	splenic	DCs.
Adoptive transfer of CD11c-βcatEX3 DCs reduces absolute CD4+ T cell responses 
and induces Tregs
To	determine	if	DCs	with	a	β-catenin	stabilization	could	be	used	as	a	potential	therapy,	




by	 any	 DC	 treatment,	 after	 four	 weeks	 CD11c-βcatEX3	 DC-treated	mice	 showed	 a	
significant	1.6-fold	 increase	 in	circulating	Tregs	(Figure	6A).	After	eight	weeks,	we	
again	isolated	splenocytes	and	cultured	them	in	the	presence	of	αCD3	for	72	hours.	
We	 found	 a	 significant	 2.4-fold	 decrease	 in	 proliferative	 capacity	 of	 T	 cells	 when	
splenocytes	were	isolated	from	mice	treated	with	control	DCs.	However,	when	CD11c-
βcatEX3	DCs	had	been	adoptively	transferred,	a	much	stronger	9.2-fold	 inhibition	of	



















































































Figure 6. Reduced T cell responses after adoptive transfer of CD11c-βcatEX3 DCs. A.	Circulating	
CD4+	T	cells	and	Tregs	(FoxP3+	within	CD4+	T	cells)	were	determined	in	the	circulation	throughout	the	
experiment.	B.	 At	 sacrifice,	 splenocytes	were	 isolated	 and	proliferation	was	 assessed	by	 the	 amount	
of 3H-thymidine	incorporation	in	dividing	cells,	expressed	as	stimulation	index	(SI).	C. IL-6	and	TNF-α	
production	by	proliferating	splenocytes	were	determined	by	ELISA.	All	values	are	expressed	as	mean±SEM	






















































































































αCD3	 staining.	 All	 values	 are	 expressed	 as	mean±SEM	 and	 are	 representative	 of	 all	 mice.*P<0.05,	
***P<0.001.
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in	CD11c+	 cells.	 It	 has	 to	be	noted	 that	while	CD11c	 is	 highly	 expressed	on	DCs,	
it	 is	 also,	 although	 to	 lower	 extent,	 expressed	 on	monocytes	 and	macrophages31,	







β-catenin	 and	 these	 only	 become	upregulated	 by	 IL-437.	 Therefore,	we	 emphasize	
















βcatEX3	chimera	 show	 significantly	 increased	 Tregs	 in	 the	 circulation	 and	 a	 general	
reduction	of	CD4+	T	cells	compared	to	control	mice.	At	sacrifice,	CD4+	T	cell	numbers	
were	also	decreased	 in	 the	 spleen	and	 the	hLNs	 indicating	an	overall	 reduction	of	






















	 In	both	our	experiments,	we	see	an	overall	 reduction	of	 the	 inflammatory	
status	in	the	CD11c-βcatEX3	mice,	not	only	by	induction	of	Tregs	and	reduction	of	Th1	
cells,	but	also	by	reduction	of	pro-inflammatory	cytokines,	e.g.	IL-6.	β-catenin	inhibits	




for	 inflammatory	 bowel	 disease,	 compared	 to	 non-modulated	 Tregs40.	 This	 further	
emphasizes	 that	 β-catenin	 stabilization	 in	 anti-inflammatory	 cell	 therapies	 is	
promising.	Activation	of	β-catenin	signaling	to	induce	tolerance	is	also	exploited	by	
the	bacterium	Salmonella,	which	produce	an	AvrA	protein.	AvrA	 induces	β-catenin	





DC	 in	vivo,	but	 it	 seems	 that	DCs	remain	 in	a	more	anti-inflammatory	 tolerogenic	
state	when	β-catenin	is	stabilized	during	atherosclerosis	development	as	they	produce	
less	pro-inflammatory	cytokines	and	increase	Treg	responses.














signaling	 cascade45,	which	 induces	β-catenin.	 Interestingly,	 these	approaches	have	
been	 implicated	 in	 inducing	 a	 tolerogenic	 phenotype	 of	 DCs.	 Another	 approach	
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could	be	cluster	disruption24,	but	it	remains	to	be	determined	how	controllable	and	
reproducible	 this	 is	 for	 a	 clinical	 setting.	However,	 since	 all	 these	 treatments	 only	
indirectly	 result	 in	β-catenin	accumulation	and	will	 inevitably	have	other	effects,	 it	
needs	to	be	established	to	what	extent	these	approaches	will	resemble	our	β-catenin	
stabilization.	A	chemical	stabilizer	of	β-catenin	could	circumvent	this	problem.	SKL2001	
e.g.	 has	been	 shown	 to	 increase	 transcription	of	 β-catenin	but	 also	 to	prevent	 its	
phosphorylation	and	degradation	and	 it	could	be	 interesting	 to	 test	 its	efficiency46.	
Moreover,	direct	administration	of	such	a	reagent	and	targeting	it	to	DCs	in	vivo	could	
prove	as	the	best	and	least	invasive	treatment	option.	
	 In	 conclusion,	 we	 show	 here	 for	 the	 first	 time	 that	 DCs	 with	 a	 β-catenin	
stabilization	 are	 highly	 potent	 inducers	 of	 Tregs,	 inhibit	 Th1	 responses	 and	 T	 cell	
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	 In	 recent	 years	 the	 immunomodulatory	 capacity	 of	 MSCs	 has	 been	
increasingly	 appreciated.	 Several	 studies	 have	 investigated	 the	 capacity	 of	 MSCs	
to	modulate	 both	 adaptive	 and	 innate	 immune	 responses2,9–14.	 For	 instance,	MSCs	








	 Inflammatory	processes	play	a	crucial	 role	 in	all	 stages	of	atherosclerosis.	
Early	in	the	disease	process,	entrapped	oxidized	low-density	lipoprotein	(oxLDL)	leads	
to	the	activation	of	arterial	endothelial	cells	and	an	ensuing	recruitment	of	monocytes	





and	 foam	 cell	 formation,	 and	 toll-like	 receptors,	which	mediate	maturation	 of	 the	
antigen-presenting	cells	and	production	of	pro-inflammatory	cytokines.	CD4+	T	cells	




by	 enhancing	 maturation	 and	 activation	 of	 antigen-presenting	 cells,	 increasing	
macrophage	 lipid	 uptake,	 reducing	 collagen	 production	 by	 SMCs,	 and	 enhancing	
expression	of	endothelial	adhesion	molecules,	which	subsequently	stimulates	leukocyte	










and	 reduce	 inflammation,	may	be	a	 therapeutic	 approach	 to	 treat	 atherosclerosis.	
Preclinical	studies	have	already	shown	that	adoptively	transferred	MSCs	are		capable	
of	modulating	 immune	 responses	 and	 they	 can	 prevent	 allograft	 rejection17,29 and 
alleviate	autoimmune	diseases30–32.	Moreover,	in	a	phase	II	clinical	trial,	it	was	found	
that	MSCs	can	reduce	graft-versus-host	disease33.	We	now	investigated	the	capacity	
of	murine	MSCs	 to	affect	 the	 inflammatory	process	of	atherosclerosis	and	 thereby	
atherosclerotic	lesion	development.











Aldrich)	 in	 the	 presence	 of	 20	 ng/mL	 granulocyte-macrophage	 colony-stimulating	
factor	 (Peprotech).	DC	purity	was	assessed	by	CD11c	expression	 (flow	cytometry)	
and	routinely	found	to	be	above	95%.
MSC isolation, phenotyping and labelling
Bone	marrow	cells	were	obtained	by	flushing	 femurs	with	washing	medium	 (RPMI	
supplemented	with	2%	FCS,	penicillin,	streptomycin	and	L-glutamine).	Next	the	bone	
marrow	cells	were	 cultured	 in	 a	75	 cm2	flask	 containing	αMEM	 (Life	Technologies)	
supplemented	 with	 10%	 FCS	 (Greiner	 Bio-One),	 2%	 penicillin/streptomycin	 (Life	
Technologies)	and	1%	L-Glutamine	(Life	Technologies;	MSC	medium).	Subsequently,	













succinimidyl	 ester	 (CFSE)	 according	 to	 manufacturer’s	 protocol	 (Thermo	 Fisher	







petri	 dishes	 (Greiner	 Bio-One)	with	 indicated	 ratios	 of	MSCs	 for	 24	 hours	 in	MSC	
medium.	DCs	were	stimulated	with	100	ng/mL	LPS	to	determine	cytokine	responses.	










RPMI	 1640,	 supplemented	 with	 10%	 FCS,	 100	 U/ml	 penicillin/streptomycin,	 2mM	
L-glutamine	(all	obtained	from	PAA)	and	20	μm	β-mercaptoethanol	(Sigma	Aldrich).	














Mice	 were	 sacrificed	 and	 subsequently,	 blood	 and	 spleen	 were	 harvested.	 White	
blood	cells	were	obtained	as	described	above.	3	x	105	cells	per	sample	were	stained	
with	 the	 appropriate	 FACS	 antibodies.	 The	 following	 antibodies	 were	 used:	 Ly-6G	
(clone	1A8;	BD	Biosciences),	CD11b	(clone	M1/70),	CD11c	(clone	N418),	CD4	(clone	









In Vivo Imaging Systems (IVIS)
For	MSC	tracking	experiments,	1	x	106	MSCs	were	stained	with	CFSE	and	 injected	





To	 determine	 plaque	 size,	 10	 µm	 cryosections	 of	 the	 aortic	 root	 were	 stained	
with	 Oil-Red-O	 and	 haematoxylin	 (Sigma	 Aldrich).	 Corresponding	 sections	 were	
stained	 for	 collagen	 fibers	 using	 the	 Masson’s	 Trichrome	 staining	 (Sigma	 Aldrich)	
or	 immunohistochemically	with	an	antibody	against	a	macrophage-specific	antigen	
(MOMA-2,	 polyclonal	 rat	 IgG2b,	 1:1000,	 Serotec	 Ltd.).	 Goat	 anti-rat	 IgG	 alkaline	
phosphatase	 conjugate	 (dilution	 1:100;	 Sigma	 Aldrich)	 was	 used	 as	 a	 secondary	










mRNA	was	 isolated	 from	the	 liver	using	 the	guanidium	 isothiocyanate	method	and	
reverse	transcribed	(RevertAid	Moloney	murine	leukemia	virus	reverse	transcriptase).	
Quantitative	gene	expression	analysis	was	performed	on	a	7500	Fast	real-time	PCR	




Scd1:		 	 5’- TACTACAAGCCCGGCCTCC-3’  and 5’-CAGCAGTACCAGGGCACCA-3’
SREBP-1c:		 5’-TCTGAGGAGGAGGGCAGGTTCCA-3’ and	5’-GGAAGGCAGGGGGCAGATAGCA-3’
SREBP-2:		 5’-TGAAGCTGGCCAATCAGAAAA-3’  and 5’-ACATCACTGTCCACCAGACTGC-3’
SDHA:		 	 5’-TATATGGTGCAGAAGCTCGGAAGG-3’  and 5’-CCTGGATGGGCTTGGAGTAATCA-3’









During	 the	 experiment,	 mice	 were	 weighed	 and	 blood	 samples	 were	 obtained	 by	
tail	 vein	 bleeding.	 Serum	 concentrations	 of	 total	 cholesterol	 were	 determined	 by	
enzymatic	colorimetric	assays	(Roche	Diagnostics).	Precipath	(standardized	serum;	






















































DCs only ½ MSC per DC 1 MSC per DC 2 MSCs per DC
CD80 95.5 ± 0.3 97.5 ± 0.4 98.2 ± 0.1 98.2 ± 0.1
CD86 68.1 ± 0.7 73.8 ± 0.3 (***) 76.0 ± 0.1  (***) 76.5 ± 0.1  (***)
CD40 88.9 ± 0.3 92.1 ± 2.0 90.1 ± 0.8 93.43 ± 0.2
OX40L 35.5 ± 0.8 47.6 ± 3.7 (*) 43.2 ± 1.1 44.1 ± 0.4
CD30L 18.2 ± 1.9 17.6 ± 1.2 19.5 ± 1.2 21.1 ± 1.5 
PD-L2 50.9 ± 0.6 56.5 ± 2.3 61.8 ± 0.9 (**) 62.5 ± 0.15 (**)
CD80 12666 ± 118 15568 ± 407 (***) 16351 ± 321 (***) 16961 ± 272 (***)
CD86 49906 ± 446 55290 ± 957 (***) 52075 ± 55 49102 ± 75
CD40 12447 ± 177 12065 ± 1148 11825 ± 287 12622 ± 12
OX40L 7439 ± 78 7655 ± 221 8196 ± 139 8135 ± 91
CD30L 2943 ± 41 2953 ± 53 2924 ± 32 3018 ± 59

















Figure 2. MSCs affect innate and adaptive immune responses. A. DCs	 were	 co-cultured	 with	
indicated	ratios	of	MSCs	for	3	hours	prior	to	addition	of	100	ng/mL	LPS	for	24	hours.	DCs	numbers	remained	


































































































































































































































































































atherosclerosis,	 LDLr-/-	mice	were	 treated	with	 three	 i.v.	 injections	 of	MSCs	 every	





































Medium         2 x 106 0.25 x 106 0.5 x 106 1 x 106 2 x 106






0 hrs                1 hrs                 3 hrs                  5 hrs







other	day	prior	 to	 induction	of	atherosclerosis	by	WTD	 feeding.	One	day	after	 the	
start	of	WTD,	we	found	a	significant	38%	drop	in	circulating	CD4+	T	cells	(8.7%	vs	









Total	 CD8+	 T	 cell	 numbers	 were	 not	 affected	 by	MSC-treatment	 in	 the	 circulation	
throughout	the	entire	experiment	(Figure	5A)	and	were	also	not	affected	in	the	spleen	







significantly	 reduced	 circulating	monocytes	by	33%,	which	was	directly	 associated	
















































































































































































































Figure 6. MSC treatment reduces VLDL production. A. Body	weight	 and	 cholesterol	 levels	were	



































































































































































































































Figure 5. MSC-treatment affects CD8+ T cell and monocyte responses in vivo. A. CD8+	T	cells	
were	measured	 in	 the	circulation	 throughout	 the	entire	experiment	by	flow	cytometry.	B.	After	eight	
weeks,	splenic	CD8+	T	cells	were	determined	by	flow	cytometry.	C.	Effector	CD8+	T	cells,	determined	
as	 CD62L-	within	 CD8+	 T	 cells,	 in	 the	 circulation	 and	 spleen	were	 determined	 by	 flow	 cytometry.	D. 
Splenocytes	were	isolated	and	stimulated	with	αCD3/CD28	for	72	hours.	Proliferation	was	assessed	by	
the	amount	of	3H-thymidine	incorporation.	Proliferation	is	normalized	for	proliferation	of	controls	(without	













































































Here	 we	 show	 that	 MSC	 treatment	 may	 be	 a	 promising	 strategy	 to	 reduce	




While	 this	 reduction	 was	 only	 observed	 initially	 after	 MSC	 transfer	 and	 induction	






of	 T	 cell	 differentiation	 both	 in	 vivo	 and	 in	 vitro,	 we	 hypothesized	 that	 additional	






and	 serum	CCL2	 levels,	 again	 clearly	 suggesting	 reduced	 immune	 responses.	This	







indicating	 that	 the	 effects	 of	MSCs	 could	 be	 indirect,	 e.g.	 by	modulation	 of	 other	
cell	types.	Previous	studies	have	found	a	link	between	immune	cells	and	cholesterol	
metabolism.	 For	 example	 lymphotoxins,	which	 are	 expressed	 by	CD4+	 T	 cells	 and	
DCs,	play	a	role	in	the	homeostasis	of	these	cells,	but	can	also	contribute	to	metabolic	
disease35,36.	 CD4+	 T	 cell	 expression	 of	 LIGHT,	 another	 ligand	 of	 the	 lymphotoxin	
receptor,	 increases	 plasma	 cholesterol	 levels,	 again	 showing	 a	 direct	 link	 between	





immune	 cells,	 affected	VLDL	 synthesis,	 by	downregulation	of	Scd1,	SREBP-1c	and	
SREBP-2.	 For	 example,	 TNF-α,	 which	 is	 downregulated	 upon	MSC	 and	 splenocyte	

































stem	 cells	 into	 SCID,	 NOG	 or	 NSG	mice44,45.	 Also,	 a	 more	 humanized	 cholesterol	
metabolism,	such	as	in	the	ApoE*3/CETP-Leiden	mice46,	would	enable	a	confirmation	
of	 effects	 observed	 on	 VLDL	metabolism.	 Taken	 together,	 our	 study	 provides	 first	
evidence	that	a	MSC-based	treatment	strategy	for	atherosclerosis	may	be	beneficial.	
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Objective Staphylococcus aureus cell	 wall	 components	 can	 induce	 IL-10	
responses	 by	 immune	 cells,	 which	 may	 result	 in	 atheroprotection.	 Here	 we	 thus	
investigated	 whether	 heat-killed	 Staphylococcus aureus	 (HK-SA)	 could	 reduce	
atherosclerosis	by	modulation	of	macrophage	function.
Methods and Results	 We	 administered	 HK-SA	 twice	 weekly	 intraperitoneally to 
LDL	receptor-deficient	mice,	which	were	subsequently	put	on	a	Western-type	diet	for	
six	weeks.	HK-SA	administration	resulted	in	an	immediate	significant	1.6-fold	increase	








macrophages	 with	 HK-SA	 in	 vitro.	 This	 resulted	 in	 a	 significant	 TLR2-dependent	
increase	 in	 IL-10,	 arginase-1,	 iNOS,	 TNF-α,	 PD-L1,	 CCL22,	 and	 IDO	 expression.	
PI3K	 was	 found	 to	 crucially	 determine	 the	 balance	 of	 pro-	 and	 anti-inflammatory	
gene	 expression.	 The	 HK-SA-induced	 macrophage	 phenotype	 resembles	 M2b-like	
immunoregulatory	macrophages.















while	 e.g.	 IL-4	 can	 induce	 alternatively	 activated	 M2	 macrophages,	 characterized	
by	an	upregulation	of	arginase-1	and	 IL-10	production3,4.	The	specific	 role	of	each	





reduced	 lesional	 macrophages9,	 decreased	 lesional	 IFN-γ-producing	 T	 cells6 and 
inhibition	of	T	cell	activation	and	proliferation10.
	 Macrophages,	 as	well	 as	DCs,	 recognize	 pathogen-	 and	danger-associated	





	 TLRs	 recognize	 various	 highly	 conserved	 molecules	 and	 TLR2	 and	 TLR4	
signaling	 in	 the	 atherosclerotic	 plaque	 has	 been	 mainly	 associated	 with	 pro-
inflammatory	cytokine	production	by	lesional	macrophages11,12.	TLR2	and	TLR4	both	
recruit	 intracellular	 myeloid	 differentiation	 primary-response	 protein	 88	 (MyD88),	
and	 the	MyD88	 adaptor-like	 protein	 (MAL),	which	 result	 in	 downstream	activation	
of	nuclear	factor	(NF)-κB	and	activating	protein-1	(AP-1).	TLR4	additionally	results	






ensure	 a	 return	 to	 immune	 homeostasis	without	 inducing	 damage	 to	 the	 affected	
tissue.	 LPS/TLR4	 stimulation	 of	 monocytes	 results	 in	 a	 late	 anti-inflammatory	 IL-
10	response	to	downregulate	the	primary	induction	of	pro-inflammatory	cytokines14.	
Similarly,	it	has	been	found	that	TLR2	can	induce	anti-inflammatory	IL-10	responses15.	








in	 the	Staphylococcal	 cell	wall18.	 Indeed,	peptidoglycan	 induced	an	 IL-10	 response	
in	 human	 macrophages	 via	 TLR2/PI3K,	 which	 resulted	 in	 the	 inhibition	 of	 T	 cell	
proliferation.	However,	stimulation	of	DCs	with	peptidoglycan	resulted	in	an	induction	
of	T	helper	(Th)	1	and	Th17	responses,	 indicating	 that	not	only	 the	 ligand	and	 its	
kinetics,	but	also	the	cell	type	involved	determines	the	type	of	immune	response19.
	 In	 this	 study	we	 established	 that	 exposure	 of	macrophages	 to	 heat-killed	






C57BL/6,	 LDLr-/-	 and	 TLR2-/-	 mice	 were	 originally	 obtained	 from	 the	 Jacksons	
Laboratory,	 kept	 under	 standard	 laboratory	 conditions,	 and	administered	 food	and	
water ad libitum.	All	animal	work	was	approved	by	the	Ethics	Committee	for	Animal	
Experiments	of	Leiden	University	and	conforms	to	Dutch	government	guidelines.	











	 For	 in	vitro	stimulations,	1	x	105	cells	per	well	were	plated	 in	96-well	flat-
bottom	plates	(Greiner	Bio-One)	 for	analysis	of	cytokine	production	by	ELISA	or	5	
x	105	per	well	 in	24-well	plates	 (Greiner	Bio-One)	 for	mRNA	 isolation.	 	Cells	were	
stimulated	with	 indicated	 amounts	 of	 heat-killed	Staphylococcus aureus	 (tlrl-hksa,	
Invivogen)	for	24	hours.	
Atherosclerosis 
Atherosclerosis	 was	 induced	 in	 10-12	weeks	 old	 female	 LDLr-/-	mice	 by	 feeding	 a	
Western-type	 diet	 (WTD;	 0.25%	 cholesterol	 and	 15%	 cocoa	 butter;	 Special	 Diet	
























against	 a	 macrophage	 specific	 antigen	 (MOMA-2,	 polyclonal	 rat	 IgG2b,	 1:1000,	
Serotec	 Ltd.).	 Goat	 anti-rat	 IgG	 alkaline	 phosphatase	 conjugate	 (dilution	 1:100;	
Sigma	 Aldrich)	 was	 used	 as	 a	 secondary	 antibody	 and	 nitro	 blue	 tetrazolium	 and	
5-bromo-4-chloro-3-indolyl	phosphate	as	enzyme	substrate.	To	determine	the	number	
of	 adventitial	 T	 cells,	 CD3	 staining	 was	 performed	 using	 anti-mouse	 CD3	 (clone	
SP7,	1:150,	ThermoScientific).	BrightVision	anti-rabbit-HRP	was	used	as	secondary	
antibody	(Immunologic).	The	section	with	the	largest	lesion	and	four	flanking	sections	






mRNA	 was	 isolated	 from	 macrophages	 and	 the	 aortic	 arch	 using	 the	 guanidium	
isothiocyanate	method	and	reverse	transcribed	(RevertAid	Moloney	murine	leukemia	
virus	 reverse	 transcriptase).	Quantitative	 gene	 expression	 analysis	was	 performed	
on	 a	 7500	 Fast	 real-time	 PCR	 system	 (Applied	 Biosystems)	 using	 SYBR	 Green	












serum;	 Roche	 Diagnostics)	 was	 used	 as	 internal	 standard.	 The	 distribution	 of	
cholesterol	over	the	different	lipoproteins	in	serum	was	determined	by	fractionation	
of	30	µl	of	serum	of	each	mouse	using	a	Superose	6	column	(3.2	x	300	mm,	Smart-




Table 1. Primer Pairs used for qPCR analysis. The	 relative	 expression	 of	 genes	was	 determined	
relative	 to	 the	 average	 expression	 of	 the	 three	 household	 genes:	 succinate	 dehydrogenase	 complex,	
subunit	 A,	 flavoprotein	 (Sdha),	 hypoxanthine	 phosphoribosyltransferase	 (HPRT),	 and	 60S	 ribosomal	






























HK-SA potently induces IL-10 responses upon intraperitoneal administration
Peptidoglycan-embedded	lipopeptides	and	glycopolymers	in	the Staphylococcus aureus 
cell	wall	have	been	shown	to	 induce	IL-10	responses18,19.	We	therefore	determined	
whether	intraperitoneal	injections	with	108	colony-forming	units	HK-SA	could	induce	
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was	 observed	 (control:	 19.3	 ±	 2.8	 versus	 HK-SA:	 8.6	 ±	 1.5	 T	 cells	 per	 section;	












	 Because	 CCL2	 plays	 a	 crucial	 role	 in	 the	 recruitment	 of	 monocytes	 to	
atherosclerotic	lesions,	we	assessed	monocyte	responses.	Overall	monocyte	numbers	

























































Figure 3. Intraperitoneal injections of HK-SA do not affect weight and cholesterol. After six 





HK-SA treatment reduces Th1, Th2 and Th17 responses in vivo







5B).	 Next,	we	 isolated	 splenocytes	 from	 control	 and	HK-SA-treated	mice	 after	 six	
weeks	WTD	and	stimulated	them	ex	vivo	to	assess	their	proliferative	capacity.	Upon	




HK-SA induces an IL-10-producing immunoregulatory M2b-like phenotype in 
macrophages
To	further	delineate	the	effects	of	HK-SA	on	macrophages	we	cultured	bone	marrow-
derived	macrophages	 and	 treated	 these	with	 increasing	 amounts	 of	HK-SA	 (up	 to	





















































































































































	 As	 recognition	of	 pathogens	 is	 associated	with	macrophage	activation	and	
phenotype	 changes,	 we	 determined	 whether	 HK-SA	 exposure	 induced	 a	 specific	
macrophage	subset.	Exposure	to	HK-SA	induced	some	markers	of	inflammatory	M1	
macrophages:	a	significant	upregulation	of	iNOS	(220-fold)	and	TNF-α	(5-fold)	was	
observed	 (Figure	 6B).	 TNF-α	 and	 iNOS	 have	 also	 been	 described	 to	 be	 produced,	
in	 parallel	 with	 IL-10,	 by	 immunoregulatory	 M2b	macrophages21,22 and indeed we 
saw	an	18-fold	upregulation	of	 IL-10	and	a	45-fold	upregulation	of	arginase-1,	an	
M2	marker23,24,	 upon	 treatment	 with	 108	 colony-forming	 units	 HK-SA	 (Figure	 6C).	
Additionally	we	observed	a	6-fold	upregulation	of	CCL22,	a	30-fold	upregulation	of	
IDO	and	a	6-fold	upregulation	of	 PD-L1;	 all	 anti-inflammatory	markers25,26	 (Figure	
6D).	Other	markers	of	M2	subsets,	such	as	CD163	(M2a,c)	and	TGF-β	(M2c)23,24	were 

























































































































































































profile	 indicates	 that	 macrophages	 are	 skewed	 towards	 immunoregulatory	 M2b	
macrophages	with	an	overall	anti-atherogenic	phenotype	upon	HK-SA	exposure.
IL-10 responses to HK-SA are TLR2/PI3K-dependent 
The	 Staphylococcus aureus	 cell	 wall	 contains	 TLR2	 ligands	 and	 we	 therefore	
tested	whether	 the	 observed	 anti-inflammatory	 IL-10	 response	was	 dependent	 on	
TLR2	 ligation.	 Indeed,	 upon	 stimulation	 with	 108	 colony-forming	 units	 of	 HK-SA,	
macrophages	 of	 TLR2-/-	 mice	 produced	 74%	 less	 IL-10	 than	 wild-type	 controls.	








significantly	 increased	 TNF-α	 and	 iNOS	 expression,	 and	 interestingly	 also	 induced	
a	significant	expression	of	IL-12.	In	 line	with	IL-10	responses,	also	arginase-1	was	
significantly	reduced.	Surprisingly,	IDO	was	however	upregulated	by	PI3K	inhibition	
(Figure	 7C).	 Therefore,	 it	 seems	 that	 anti-inflammatory	 IL-10	 responses	 are	

































































































































































































a	 distinct	macrophage	 phenotype,	 we	 looked	 at	 the	 gene	 expression	 signature	 of	









































































































































































been	shown	 to	be	potent	 immunoregulators	and	can	even	protect	mice	 from	LPS-
induced	 septic	 shock22.	 Additionally,	 the	 M2	marker	 arginase-1	 is	 induced	 by	 HK-
SA	treatment.	After	stimulation	with	HK-SA,	we	find	that	macrophages	also	express	
anti-inflammatory	 IDO,	 PD-L1	 and	 CCL22.	 IDO	 expression	 is	 known	 to	 suppress	
CD4+ T	cell	responses	and	induce	Tregs25.	PD-L1	also	plays	a	crucial	role	in	inducing	
and	maintaining	Tregs26,	while	CCL22	plays	a	role	in	Treg	recruitment.	We	therefore	
conclude	 that	 HK-SA	 is	 capable	 of	 inducing	 a	 specific	 anti-inflammatory	 M2b-like	
macrophage	signature.
	 The	 observed	 anti-inflammatory	 IL-10	 response	 was	 largely	 dependent	
on	 TLR2.	 However,	 as	 IL-10	 responses	 are	 not	 completely	 inhibited	 in	 TLR2-/-
macrophages,	 other	 receptors	 (including	 scavenger	 receptors,	 NOD-like	 receptors,	
or	 other	 TLRs)	 recognizing	 HK-SA	 components	 likely	 contribute	 to	 induce	 IL-10	
responses.	For	example,	NOD-like	receptor	signaling	is	induced	by	peptidoglycan	and	
triggers	RIP2-dependent	activation	of	NF-κB.	The	purified	gram	positive	Streptococcus 
pneumonia,	 which	 mostly	 consists	 of	 peptidoglycan,	 was	 found	 to	 induce	 TLR2-
dependent	IL-10	responses,	which	were	also	largely	dependent	on	NOD2-signaling32.	












Surprisingly	 PI3K	 also	 inhibits	 anti-inflammatory	 IDO	expression	 by	macrophages,	
suggesting	that	it	plays	a	crucial	role	in	balancing	several	pro-	and	anti-inflammatory	
responses	to	HK-SA	in	macrophages.	Interestingly,	PI3K	has	been	suggested	to	be	
involved	 in	 determining	 the	 macrophage	 phenotype	 and	 increased	 PI3K	 signaling	
has	 been	 found	 to	 skew	 macrophages	 to	 an	 M2	 phenotype40.	 In	 the	 context	 of	
atherosclerosis,	 only	 class	 Ib	 PI3K	 deficiency	 has	 been	 investigated	 and	 no	 effect	










agonist)	 and	MALP2	 (TLR2/TLR6	 agonist)	 result	 in	 increased	 atherosclerotic	 lesion	
formation45–47.	 Deficiency	 of	 either	 TLR1	 or	 TLR6	 was	 found	 to	 have	 no	 effect	 on	





and	 Pam3Csk4	 were	 found	 to	 reduce	 ischaemia/reperfusion	 injury	 in	 a	 PI3K-
dependent	way49.	Moreover,	intranasal	Pam3Csk4	administration	suppressed	asthma	
development50,	while	 intraperitoneal	administration	reduced	type	1	diabetes51,	both	
















	 In	 summary,	 we	 demonstrate	 that	 HK-SA	 treatment	 significantly	 reduces	
atherosclerotic	lesion	development	by	34%,	likely	through	inducing	IL-10-producing	
immunoregulatory	M2b-like	macrophages	upon	intraperitoneal	treatment.	Our	results	
indicate	 that	 TLR2/PI3K	 activation	 in	 macrophages	 via	 HK-SA	 could	 be	 beneficial	
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Objective	 Regulatory	T	cells	 (Tregs)	play	an	 important	 role	 in	 the	 regulation	
of	 T	 cell-mediated	 immune	 responses	 through	 suppression	 of	 T	 cell	 proliferation	
and	cytokine	production.	In	atherosclerosis,	a	chronic	autoimmune-like	disease,	an	
imbalance	 between	 pro-inflammatory	 cells	 (Th1/Th2)	 and	 anti-inflammatory	 cells	
(Tregs)	 exists.	 Therefore,	 increased	 Treg	 numbers	 may	 be	 beneficial	 for	 patients	
suffering	from	atherosclerosis.	In	the	present	study,	we	determined	the	effect	of	a	
vast	expansion	of	Tregs	on	the	initiation	and	regression	of	well-established	lesions.	
Methods and Results	 For	 in	vivo	Treg	expansion,	LDL	receptor	deficient	(LDLr-/-)	
mice	received	repeated	 intraperitoneal	injections	of	a	complex	of	IL-2	and	anti-IL-2	
mAb.	This	resulted	in	a	10-fold	increase	in	CD4+CD25hiFoxp3+	T	cells,	which	potently	
suppressed	 effector	 T	 cells	 ex	 vivo.	 During	 initial	 atherosclerosis,	 IL-2	 complex	
treatment	 of	 LDLr-/-	 mice	 fed	 a	 Western-type	 diet	 reduced	 atherosclerotic	 lesion	
formation	 by	 39%.	 The	 effect	 on	 pre-existing	 lesions	was	 assessed	 by	 combining	
IL-2	complex	treatment	with	a	vigorous	lowering	of	blood	lipid	levels	in	LDLr-/-	mice.	









Atherosclerosis	 is	 considered	 to	 be	 a	 chronic	 autoimmune-like	 disease	 with	 an	
underlying	imbalance	between	pro-inflammatory	and	anti-inflammatory	processes1,2.	
Restoration	of	this	delicate	balance	by	induction	of	Tregs	has	proven	to	be	of	therapeutic	
potential	 in	 the	 treatment	 of	 several	 autoimmune	 diseases	 such	 as	 diabetes	 and	
rheumatoid	arthritis3,4.	As	key	regulators	of	T	cell-mediated	immune	responses,	Tregs	

















	 In	 order	 to	 obtain	 a	 clinically	 relevant	 therapy	 for	 atherosclerosis,	 an	
experimental	 therapy	 inducing	 regression	 of	 atherosclerosis	 is	 a	 prerequisite,	 as	






Material and methods 
Animals
Male	 LDLr	 deficient	 (LDLr-/-)	 mice,	 10-12	 weeks	 old,	 were	 obtained	 from	 Jackson	
Laboratories.	The	animals	were	kept	under	standard	laboratory	conditions	and	were	










Initiation and regression of atherosclerosis





























Biosciences	Pharmingen,	San	Diego.	CA).	 In	addition,	 the	aortic	arch	and	 its	main	



















CD4,	CD25	and	Foxp3.	 In	addition,	 cells	were	stained	 for	 the	 transcription	 factors	




Splenocytes	(n=5	per	group)	were	cultured	 for	48	hours	 in	 triplicate	 in	a	96-wells	
round-bottom	plate	(3	×	105	cells/well)	in	RPMI	1640	supplemented	with	L-Glutamine,	








Tregs	 were	 isolated	 with	 greater	 than	 95%	 purity	 from	 splenocytes	 using	 the	
CD4+CD25+	Regulatory	T	Cell	Isolation	Kit	from	Miltenyi	Biotec.	7.5	×	104	splenocytes	
were	plated	out	per	well	of	a	96-well	plate	with	or	without	titrated	amounts	of	isolated	

















IL-10:		 5’-TCTTACTGACTGGCATGAGGATCA-3’		 and		 5‘-GTCCGCAGCTCTAGGAGCAT-3’
TGF-β:		 5’-AGGGCTACCATGCCAACTTCT-3’		 and		 5‘-GCAAGGACCTTGCTGTACTGTGT-3’
The	following	primers	were	used	as	endogenous	references:	
36B4:	 5’-GGACCCGAGAAGACCTCCTT-3’		 and		 5’	GCACATCACTCAGAATTTCAATGG-3’	
























































































IL-10              TGF-β
***
Figure 1. IL-2 complex induces persistent high levels of Tregs in LDLr−/− mice. LDLr-/-mice were 
injected	3	times	with	an	IL-2	complex	(n	=	3,	black	bars)	or	PBS	as	a	control	(n	=	3,	open	bars).	Mice	
















Persisting high levels of Tregs in LDLr-/- mice due to continuous treatment 
with the IL-2 complex
To	 determine	whether	 IL-2	 complexes	 induced	 Treg	 expansion	 in	 LDLr-/-	mice,	 we	
injected	 the	 IL-2	 complex	 or	 PBS	 intraperitoneally	 on	 3	 consecutive	 days.	 Mice	
were	sacrificed	5	days	after	initiation	of	the	experiment.	The	administration	of	IL-2	
complexes	resulted	in	a	significant	3-fold	increase	of	Tregs	in	lymphoid	organs	and	
an	11-fold	 increase	 in	 the	 liver,	 compared	 to	 control	mice	 (Figure	1A	and	B).	The	
expanded	Tregs	in	the	IL-2	complex-treated	group	were	functional	as	they	potently	
suppressed	effector	T	cell	proliferation	ex	vivo	(Figure	1C).	In	addition,	Tregs	expanded	














persistently	 remained	at	a	significantly	10-fold	higher	 level	 than	 in	control	 treated	
mice	(P<0.001).
IL-2 complex administration reduces the development of atherosclerosis 
Since	 a	 limited	 increase	 in	 Tregs	 already	 affects	 initiation	 of	 atherosclerosis,	 we	
postulated	 that	a	10-fold	expansion	of	Tregs	 in	blood	observed	after	 IL-2	complex	
administration	 may	 significantly	 potentiate	 this	 effect.	 During	 the	 experiment	
enhanced	 levels	 of	 Tregs	 did	 not	 affect	 body	 weight	 and	 total	 plasma	 cholesterol	
levels	(data	not	shown).	Eight	weeks	after	the	start	of	the	high	fat	diet	mice	were	
sacrificed	and	atherosclerotic	lesion	size	was	determined.	We	observed	a	significant	
39%	reduction	 in	aortic	root	 lesion	size	of	IL-2	complex	treated	mice	(1.73×105 ±	
0.13×105 μm2)	in	comparison	with	control	mice	(2.84×105 ±	0.30×105	μm2,	P<0.01,	

















(Figure	 3B,	 P<0.05).	 Since	 Tregs	 function	 in	 part	 via	 IL-10	 and	 TGF-β	 secretion,	
we	determined	the	gene	expression	of	these	cytokines	in	the	spleen.	IL-2	complex	
treated	mice	showed	a	4.7-fold	increase	in	IL-10	expression	compared	with	control	
mice	 (P<0.05),	 whereas	 TGF-β	 expression	 remained	 unchanged	 (Figure	 3C).	 This	
suggests	that	Tregs	induced	by	the	IL-2	complex	may	exert	their	suppressive	function	
predominantly	via	the	secretion	of	IL-10.
Effect of Treg expansion on other T cell subsets 
It	has	been	suggested	that	Tregs	have	the	capacity	to	specifically	target	and	suppress	
effector	T	cells,	such	as	Th1,	Th2	and	Th17	cells19,20.	To	evaluate	whether	the	IL-2	












































































IL-2 complex-expanded Tregs stabilize lesions in a regression model
Since	 it	 is	clinically	more	relevant	 to	determine	 the	effect	of	Tregs	on	pre-existing	
lesions,	we	combined	lipid	lowering	with	IL-2	complex	treatment.	To	this	end,	we	put	
LDLr-/-	mice,	which	were	fed	a	Western-type	diet	 for	10	weeks,	on	a	chow	diet	 for	
another	 10	weeks,	 combined	with	 simultaneous	 administration	 of	 IL-2	 complexes.	
In	addition,	a	baseline	group	was	sacrificed	after	10	weeks	of	Western-type	diet	to	
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treated	mice	 during	Western-type	 diet	 feeding	 (Figure	 4A	 and	 B).	 In	 addition,	 no	
differences	in	weight	were	found	between	control	and	IL-2	complex-treated	mice	after	
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Figure 4. Effect of IL-2 complex on weight, cholesterol levels and Tregs during regression 
of atherosclerosis. LDLr-/-	mice	received	10	weeks	Western-type	diet	and	were	subsequently	put	on	


























In	 addition,	we	analyzed	 the	aortic	 root	 for	CD3+	 T	 cells	within	 lesions	 and	 found	

























































Figure 5. IL-2 complex treatment stabilizes atherosclerotic lesions during regression. 
A.	Sections	of	the	aortic	root	were	stained	with	Oil-red-O	and	hematoxylin. B. Corresponding	sections	


















drastically	 attenuate	 atherosclerosis	 development.	We	 used	 the	 recently	 published	
technique	using	the	IL-2	complex	consisting	of	IL-2	and	a	neutralizing	anti-IL-2	mAb,	
a	treatment	that	beneficially	affected	the	outcome	of	a	number	of	autoimmune-like	
diseases16-19.	 In	 the	present	study,	LDLr-/-	mice	were	 fed	a	Western-type	diet	 for	8	
weeks.	The	treatment	with	the	IL-2	complex	was	started	after	two	weeks	of	feeding	
the	Western-type	diet	in	order	to	counteract	the	pro-inflammatory	effects	of	the	diet.	







	 The	 significantly	 strong	expansion	of	CD4+CD25hiFoxp3+	 T	 cells	 resulted	 in	
a	39%	decrease	in	initial	atherosclerosis	in	the	aortic	root.	It	was	previously	shown	




















































mainly	 focus	on	preventing	 the	 initiation	and	to	a	minor	extent	 the	progression	of	
atherosclerosis.	 A	 clinically	 more	 relevant	 therapy	 for	 atherosclerosis	 would	 be	 a	
therapy	which	 induces	 regression	 of	 atherosclerosis	 as	most	 of	 the	 cardiovascular	
patients	 already	 have	well-established	 lesions.	 In	 the	 present	 study,	we	 therefore	





(LXR)-agonist27.	 In	our	 current	 study,	we	were	able	 to	 induce	high	 levels	of	Tregs	
in	mice	 that	 previously	 were	 fed	 a	 cholesterol	 rich	 diet	 for	 10	weeks	 comparable	
to	 the	 levels	 obtained	 in	 chow	 fed	mice.	We	observed	no	 lesion	 regression	 in	 the	
control	group	(only	lipid	lowering)	and	despite	extensive	Treg	induction	also	no	lesion	
regression	was	found	in	the	IL-2	complex-treated	group.	However,	we	observed	that	














that	 these	 Tregs	 are	 functional	 in	 suppressing	 effector	 T	 cells	 and	 in	 limiting	 the	
possibility	of	effector	T	cell	expansion	and	migration	towards	inflammatory	sites.	In	
addition	to	the	apparent	phenotype	of	T	cells	in	the	IL-2	treated-group,	the	observed	
increase	 in	 IL-10	 additionally	 suggests	 an	 anti-inflammatory	 environment	 in	 these	
mice.	This	again	suggests	an	inhibition	of	effector	T	cell	proliferation	but	also	implies	
that	T	cells	found	in	this	environment	will	be	of	an	anti-inflammatory	phenotype.
	 In	 conclusion,	 our	 data	 clearly	 illustrate	 the	 potential	 of	 IL-2	 complexes	
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regulating	 proteins,	 and	 transcription	 factors.	 We	 assessed	 whether	 proteasome	
inhibition	 in	 addition	 to	 its	 effect	 on	 inflammation	 could	 affect	 lipid	metabolism	 in	
atherosclerosis-prone	low-density	lipoprotein	receptor-deficient	(LDLr-/-)	mice.
Methods and Results	 We	 found	 that	 proteasome	 inhibition	 by	 Bortezomib	
treatment	during	eight	weeks	of	Western-type	diet	resulted	in	a	robust	59%	reduction	
of	 aortic	 root	 lesion	 sizes	 in	 LDLr-/-	mice.	 These	 lesions	 show	a	 1.9-fold	 reduction	







from reduced de novo hepatic	synthesis	of	lipids,	as	determined	by	a	significant	58%	
reduction	of	fatty	acid	synthase.	Moreover,	increased	cholesterol	efflux	to	the	bile	was	
observed,	as	determined	by	a	2-fold	upregulation	of	ABCG5.














cycle	progression,	differentiation,	 apoptosis,	 cellular	 stress	 responses	and	 immune	
responses3.	 Dysregulation	 of	 the	 ubiquitin	 proteasome	 system	 is	 associated	 with	
multiple	 diseases,	 such	 as	 cancer,	 neurodegenerative	 diseases,	 viral	 infections,	
cardiovascular	disease	and	autoimmune	diseases2,4,5.
	 The	mammalian	26S	proteasome	consists	of	a	barrel-shaped	20S	core	protein	
subunit	and	one	or	 two	 regulatory	cap	proteins,	which	 recognize	polyubiquitinated	
proteins	 and	move	 them	 to	 the	 20S	 core6.	 The	 20S	 core	 degrades	 proteins	 in	 its	
hollow	center	and	consists	of	seven	α	and	seven	β	subunits,	of	which	β1,	β2	and	β5	






	 Proteasomal	 inhibition	 has	 been	 thoroughly	 investigated	 in	 cancer.	 Initial	
interest	was	driven	by	studies	showing	that	proteasomal	inhibitors	could	block	anti-
apoptotic	 nuclear	 factor	 (NF)-κB	 signaling,	 thereby	 inducing	 apoptosis	 in	 cancer	
cells.	The	inhibition	of	NF-κB	signaling	by	proteasome	inhibitors	was	attributed	to	the	











CD40,	 TNF	 receptors,	 IL-1	 receptor,	 and	 the	 T	 cell	 receptor14.	 Indeed,	 treatment	
of	 macrophages	 with	 proteasome	 inhibitors	 reduced	 TLR-induced	 responses,	 such	
as	 iNOS,	TNF-α,	and	IL-6	 induction15.	Proteasome	 inhibition	has	been	shown	to	be	
protective	 in	 experimental	 models	 of	 (collagen-induced)	 arthritis16,17,	 acute	 graft-
versus-host	disease18,19,	and	experimental	autoimmune	encephalomyelitis20.
	 The	most	well-known	and	best	studied	proteasome	inhibitor	is	the	reversible	
dipeptidyl	 boronic	 acid	 inhibitor	 Bortezomib	 (PS-341,	 Velcade®)	 which	 primarily	
blocks	 β5	 and	 β5i	 subunits,	 but	 also	 β1	 and	 β1i3.	 It	 has	 been	 approved	 by	 the	
154
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United	 States	 Food	 and	 Drug	 Administration	 (FDA)	 for	 the	 treatment	 of	 multiple	
myeloma	 and	mantle	 cell	 lymphoma21.	 Proteasomal	 inhibition	 has	 been	 previously	
addressed	in	atherosclerosis.	Herrmann	et al. have	found	increased	atherosclerosis	
in	 a	 pig	model	 of	 diet-induced	 atherosclerosis	 due	 to	 increased	 oxidative	 stress22.
In	ApoE-/-	mice	no	effect	on	early	atherosclerotic	lesions	was	found,	but	in	advanced	
stages	 of	 atherosclerosis	 Bortezomib	 induced	 rupture-prone	 lesions,	 likely	 due	 to	
increased	 smooth	muscle	 cell	 and	macrophage	 apoptosis23.	Wilck	 et al.,	 however,	

















Atherosclerosis	 was	 induced	 in	 10-12	 weeks	 old	 female	 LDLr-/-	mice	 by	 feeding	 a	












using	Qubit®	protein	assay	kit)	were	 then	 incubated	 for	1	hour	with	BODIPY(FL)-








In vivo hepatic VLDL production rate




after	60,	120,	and	180	min	 to	determine	VLDL-triglyceride	 (TG)	 levels.	The	VLDL-
TG	secretion	 rate	was	determined	by	 the	 slope	of	 the	TG	 rise	over	 time	by	 linear	
regression	analysis.
Tissue lipid analysis
Lipids	were	extracted	 from	 liver	using	 the	Folch	method	as	described	previously28.	








Plasma cholesterol levels and FPLC seperation
Plasma	concentrations	of	total	cholesterol	were	determined	by	enzymatic	colorimetric	
assays	(Roche	Diagnostics).	Absorbance	was	read	at	490	nm.	Precipath	(standardized	
serum;	 Roche	 Diagnostics)	 was	 used	 as	 internal	 standard.	 The	 distribution	 of	
cholesterol	over	the	different	lipoproteins	in	plasma	was	determined	by	fractionation	
of	30	µl	of	plasma	of	each	mouse	using	a	Superose	6	column	(3.2	x	300	mm,	Smart-
System;	 Pharmacia).	 Total	 cholesterol	 content	 of	 the	 effluent	 was	 determined	 as	
described	above.



















transcriptase).	 Quantitative	 gene	 expression	 analysis	 was	 performed	 on	 a	 7500	
Fast	real-time	PCR	system	(Applied	Biosystems)	using	SYBR	Green	technology.	The	
expression	was	determined	relative	to	the	average	expression	of	three	household	genes:	
Succinate	 dehydrogenase	 complex,	 subunit	 A,	 flavoprotein	 (Sdha),	 hypoxanthine	
phosphoribosyltransferase	(HPRT),	and	60S	ribosomal	protein	L27	(Rpl27).	For used 
primer	pairs	refer	to	Table	1.	
Table 1. Primer Pairs used for qPCR analysis. The	 relative	 expression	 of	 genes	was	 determined	
relative	to	the	average	expression	of	four	housekeeping	genes:	ribosomal	protein	36B4,	glyceraldehyde	































were	 stained	with	 the	appropriate	antibodies.	The	 following	antibodies	were	used:	
CD11b-eFluor450	(clone	M1/70),	CD4-PerCP	(clone	RM4-5;	BD	Biosciences),	CD25-
FITC	(clone	eBio3C7),	FoxP3-APC	(clone	FJK-16s),	Gata-3-PE	(clone	TWAJ),	Ly-6C-
PerCP	 (clone	 HK1.4),	 Ly-6G-FITC	 (clone	 1A8;	 BD	 Biosciences),	 RORγt-PE	 (clone	









10	 µm	 cryosections	 of	 the	 liver	 were	 stained	 with	 Oil-Red-O	 and	 hematoxylin	 to	
determine	lipid	content.	To	determine	aortic	root	plaque	size,	10	µm	cryosections	were	
stained	with	 Oil-Red-O	 and	 haematoxylin	 (Sigma	 Aldrich).	 Corresponding	 sections	
were	stained	for	collagen	fibers	using	Sirius	Red	(Sigma	Aldrich)	and	analyzed	under	
polarized	light.	Macrophage	content	was	analyzed	by	immunohistochemical	staining	
































inhibition	of	proteasome	activity	by	 the	 subunits	β1,	β1i,	 and	β5/β5i.	White	blood	
cells	in	the	circulation	showed	a	63%	reduction	of	β1	and	a	46%	reduction	of	β5/β5i	
Peritonial Cells White Blood Cells
BTZ - - - + + + - - - + + +
Liver Spleen











% inhibition Peritoneal Blood Spleen Liver
β1c 100 63 30 n.d.
β1i 100 n.d. 79 n.d.
β5 100 46 79 85
Figure 1. Bortezomib reduces proteasomal activity. Female	 LDLr-/-	 mice	 received	 two	 weekly	
injections	 of	 vehicle	 control	 (PBS/DMSO)	 or	 bortezomib	 (BTZ).	 One	 hour	 after	 the	 last	 injection,	
peritoneal	cells,	blood,	 liver	cells,	and	splenocytes	were	 isolated.	Proteasome	activity	was	determined	










































































































Proteasomal Inhibition Significantly Reduces Monocyte Recruitment and 
Macrophages
In	line	with	a	reduction	in	lesional	macrophages	in	the	aortic	root,	we	also	observed	



























































































































Figure 3. Bortezomib reduces monocytes and macrophages. A. The	expression	of	CD68,	CCL2	
and	VCAM-1	were	determined	in	the	aortic	arch	by	qPCR.	B.	The	expression	of	CD68	and	CCL2	were	
determined	in	the	liver	by	qPCR.	Expression	was	determined	relative	to	four	housekeeping	genes	(36B4,	














Proteasomal Inhibition Skews T cells towards Th2 Responses and Reduces 
Th1 Responses




mice	and	 control	mice	and	 induced	general	 T	 cell	 proliferation	by	 stimulation	with	
αCD3	and	αCD28	 for	72	hours.	We	 found	a	significant	43.4%	and	72.8%	reduced	
proliferative	 capacity,	 as	 determined	 by	 3H-thymidine	 incorporation	 and	 IL-2	
production,	 respectively	 (Figure	 4A).	 The	 relative	 percentages	 of	 T	 cell	 responses	
were	significantly	skewed	towards	Th2	responses,	which	were	increased	by	43.1%,	







































































































Proteasomal Inhibition Significantly Reduces Plasma Cholesterol and VLDL 
Secretion
During	the	entire	experiment	we	monitored	weight,	food	intake,	plasma	glucose	and	
cholesterol	 levels	 to	determine	possible	effects	on	metabolism.	While	we	 found	no	
significant	 effects	 on	 food	 intake,	 weight	 development	 and	 plasma	 glucose	 levels	
(Figure	 5A),	 we	 intriguingly	 observed	 that	 after	 one	week	WTD	 cholesterol	 levels	
plateaued	 in	 mice	 treated	 with	 Bortezomib.	 After	 eight	 weeks	 diet,	 proteasome	
inhibition	resulted	in	a	significant	50.2%	decrease	in	total	plasma	cholesterol	levels	
compared	to	control	mice	(Figure	5B).	The	large	reduction	in	cholesterol	levels	was	
due	 to	 a	 substantial	 62%	decrease	 in	 plasma	VLDL	 levels	 as	 determined	 by	 fast-
performance	liquid	chromatography	(FPLC)	separation,	while	LDL	and	HDL	levels	were	
not	affected	(Figure	5B).	
Additionally,	 we	 observed	 a	 reduction	 in	 Oil-Red	 O	 positive	 staining	 in	 livers	 of	
Bortezomib-treated	mice	(Figure	6A).	Oil-red	O	stains	neutral	lipids	(e.g.	triglycerides	
and	cholesterol	esters)	and	it	is	the	most	accurate	method	for	determining	the	level	






























































































































Figure 5. Bortezomib treatment reduces serum cholesterol levels. A.	Mice	were	weighed	weekly,	















treated	 mice	 showed	 a	 49.6%	 reduction	 in	 their	 VLDL-triglyceride	 secretion	 rate	
(Figure	 6E).	 Reduced	 VLDL	 secretion	 has	 often	 been	 seen	 to	 increase	 triglyceride	
content	of	the	liver,	but	we	did	not	observe	any	effect	on	liver	triglyceride	content.
Proteasomal Inhibition Significantly Reduces Lipogenesis and Increases Bile 
Acid Excretion
To	 determine	 if	 reduced	 VLDL	 secretion	 was	 due	 to	 reduced	 hepatic	 lipid	 uptake	
we	 assessed	 the	 expression	 of	 CD36	 and	 LDL	 receptor-related	 protein	 1	 (LRP1),	
both	 receptors	 for	 VLDL	 and	 chylomicrons.	 CD36	 and	 LRP1	 were	 not	 affected	 by	
Bortezomib-treatment	(Figure	7A),	 indicating	that	hepatic	VLDL	clearance	from	the	
circulation	was	not	affected.
	 We	 further	 assessed	 whether	 expression	 of	 genes	 involved	 in	 hepatic	 de 
novo	 lipogenesis	was	modified.	Fatty	acid	 synthase	 (FAS)	 is	 the	main	biosynthetic	





































































































































	 Sterol	 regulatory	 element	 binding	 protein-1c	 (SREBP-1c),	 a	 transcription	
factor	 regulation	 de novo lipogenesis	 genes,	 was	 also	 not	 affected	 (Figure	 7D).	
However,	peroxisome	proliferator-activated	receptor	γ	(PPARγ),	a	transcription	factor	













To	 our	 knowledge	 we	 show	 here	 for	 the	 first	 time	 that	 Bortezomib	 can	 have	 a	
potent	lipid-lowering	effect,	a	quality	that	in	addition	to	its	anti-inflammatory	effects	
strengthens	 the	 beneficial	 effect	 of	 Bortezomib	 on	 atherosclerosis.	 Bortezomib	 is	
therefore	the	perfect	dual	drug	to	inhibit	both	underlying	causes	of	atherosclerosis:	






















































































































































Figure 7. Bortezomib inhibits de novo lipogenesis.	Genes	involved	in	lipoprotein	uptake	(A),	genes	










atherosclerosis	 study	 by	Wilck	 et al. we	 observe	 a	 significant	 reduction	 in	 VCAM-
1,	CCL2	 levels	 and	monocyte	 responses24.	Moreover,	we	observe	 reduced	Th1	 cell	
induction	 and	 a	 skewing	 towards	 Th2	 cells,	which	 is	 in	 line	with	 earlier	 described	
effects	of	proteasome	inhibition	on	CD4+	T	cell	subsets31.	Anti-inflammatory	effects	
of	 Bortezomib	 have	 also	 been	 described	 in	 experimental	 models	 for	 rheumatoid	
arthritis	and	graft-versus-host	disease17,18.	Interestingly,	we	see	a	large	reduction	of	
macrophage	content	in	the	liver.	Uptake	of	oxLDL	or	cholesterol	crystals	has	been	found	
to	 increase	expression	of	 inflammatory	genes	 in	macrophages	and	may	contribute	
to	 the	development	 of	 hepatosteatosis36,37.	Non-alcoholic	 steatohepatitis	 (NASH)	 is	
dramatically	 reduced	when	 inflammatory	 responses	 of	 liver	macrophages	 (Kupffer	













liver.	Because	 LPL	 is	 secreted	by	macrophages,	 reduced	hydrolysis	 of	 triglycerides	
from	VLDL	could	result	in	less	free	fatty	acid	availability	for	VLDL	production.











genes,	 including	 SREBP-1c,	 FAS,	 Scd1,	 DGAT,	 HMG-CoA	 synthase,	 was	 observed,	







show	 a	 30-40%	 reduction	 of	 overall	 proteasomal	 activity,	 have	 increased	 SREBP-
1c	activity,	hepatic	steatosis	and	hepatic	 insulin	resistance42,	 indicating	that	the	β2	









cells43.	After	Bortezomib	 therapy	patients	did	not	show	significant	changes	 in	 their	
plasma	 cholesterol	 compared	 to	 pre-treatment	 values43,	 indicating	 that	 a	 lower	
cholesterol	level	was	maintained	despite	cancer	remission.





































Figure 8. Scheme of Bortezomib effects on hepatic lipid metabolism. Bortezomib	treatment	did	
not	affect	lipoprotein	uptake.	However	de novo	lipogenesis	is	reduced,	as	FAS	is	significantly	reduced,	
as	well	as	PPARγ.	Additionally	ABCG5	is	significantly	increased	resulting	in	increased	cholesterol	efflux.	
Overall	 this	 reduces	 hepatic	 cholesterol	 levels	 and	 reduced	 VLDL	 assembly,	 resulting	 in	 a	 decreased	
VLDL	secretion	rate.	Grey	arrows	indicate	positive	effects	of	Bortezomib-treatment.	Percentages	indicate	








73%	will	 actually	achieve	 target	plasma	LDL	 levels44	 and	a	 large	number	of	 these	
patients	will	still	have	cardiovascular	events45.	Alternatives	for	patients	unresponsive	
to	 statins	 include	 ezetimibe	 and	 bile	 acid	 sequestrants,	 but	 these	 treatments	 lack	
potency	 when	 compared	 to	 statin	 therapy46.	 For	 example,	 the	 use	 of	 ezetimibe	
in	 addition	 to	 statins	was	 recently	 assessed	 in	 the	 IMPROVE-IT	 trial	 and	 found	 to	
reduce	primary	endpoint	events,	such	as	myocardial	 infarction	and	stroke,	by	only	
an	additional	 6.4%47.	Nonetheless,	 a	proportion	of	 patients	 remain	where	none	of	
the	 above	 mentioned	 therapies	 help	 to	 reduce	 plasma	 cholesterol,	 leaving	 these	
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Atherosclerosis	 is	 the	main	underlying	 cause	of	 cardiovascular	 disease	and	mainly	
affects	 medium	 to	 large	 arteries.	 The	 disease	 develops	 due	 to	 dyslipidemia	 and	
inflammation,	 resulting	 in	 both	 a	 massive	 lipid	 accumulation	 and	 a	 chronic	 pro-
inflammatory	 response	 in	 the	vessel	wall.	Current	 treatment	 is	primarily	based	on	









The	 goal	 of	 this	 thesis	 was	 to	 establish	 novel	 immune	 cell-based	 therapies	 for	












Novel Immune Cell-Based Therapies for Atherosclerosis - Approaches
Genetically Modified 





























LDL	 (oxLDL)-induced	apoptotic	DCs	 in	both	early	and	advanced	atherosclerosis.	 It	
has	 been	 established	 that	 clearance	 of	 apoptotic	 cells	 (efferocytosis)	 in	 advanced	
atherosclerotic	 lesions	 is	 impaired3	 and	earlier	 studies	by	our	 lab	and	others	have	
shown	 that	 blockade	 of	 efferocytosis	 worsens	 atherosclerotic	 disease	 burden	





	 After	 adoptive	 transfer	 of	 apoptotic	 DCs,	 either	 before	 lesion	 initiation	 or	
after	established	 lesions	had	developed,	we	 found	 that	apoptotic	DCs	were	mainly	
cleared	 by	 DCs	 and	macrophages	 in	 the	marginal	 zone	 of	 the	 spleen,	 inducing	 a	
tolerogenic	phenotype	and	enabling	an	induction	of	Treg	responses.	Additionally,	we	
found	 that	 overall	 (inflammatory)	 monocyte	 numbers	 were	 reduced,	 a	 previously	
unknown	effect	of	apoptotic	cell	treatment.	Moreover,	in	already	established	lesions,	
which	resemble	a	more	clinical	setting	as	most	patients	enter	the	clinic	with	evident	
atherosclerosis,	 our	 treatment	was	 able	 to	 increase	 lesion	 stability.	Our	 study	 not	
only	 indicates	 the	potential	 of	 such	a	 therapeutic	 approach	 for	 the	 clinic,	 but	 also	
emphasizes	 the	 importance	 of	 research	 into	 the	 emigration	 potential	 of	 DCs	 from	
lesions.	This	is	further	reinforced	by	an	earlier	study	from	our	laboratory	showing	that	
the	 adoptive	 transfer	 of	 oxLDL-pulsed	DCs	 reduces	 initial	 atherosclerosis6.	 If	 DCs,	
which	 clear	 oxLDL	 or	 oxLDL-induced	 apoptotic	 DCs/macrophages	 (both	 containing	
atherosclerosis-relevant	antigens),	can	be	induced	to	emigrate	early	on	from	lesions,	
they	might	in	fact	contribute	to	inhibition	of	lesion	development	and	stabilization.
	 Interestingly,	 at	 the	 same	 time	 as	 we	 published	 our	 results,	 Hosseini	 et 























PS	 is	 needed	 for	 apoptotic	 cell	 recognition	 by	 DCs	 and	macrophages	 and	 inhibits	
DC	maturation12–14.	 Indeed,	 intravenous	 administration	 of	 PS-containing	 liposomes	
induces	 anti-inflammatory	 TGF-β	 and	 IL-10	 responses	 by	 macrophages,	 which	
improves	infarct	repair	after	myocardial	infarction	(MI)15.	This	approach	would	enable	
an	easier	translation	to	the	clinic	as	liposomes	could	be	generally	produced.	Indeed	








was	 previously	 suggested	 to	 be	 involved	 in	 promoting	 a	 tolerogenic	 phenotype	 in	
DCs16–18.	Indeed,	upon	bone	marrow	transplantation	of	CD11c-βcatEX3 bone marrow 
into	LDLr-/-	mice,	we	found	a	significant	increase	in	Tregs,	which	reduced	aortic	root	
lesions	 by	 26%.	 These	 lesions	 had	 significantly	 less	 necrotic	 areas	 and	 showed	 a	






















mouse	 models	 for	 experimental	 autoimmune	 encephalomyelitis,	 collagen-induced	














in	 in	 these	patients.	 Interestingly,	 in	a	small	18	patient	 cohort,	 it	was	shown	 that	
intracoronary	stem	cell	infusion	following	MI	reduced	plaque	burden	in	the	coronary	
tree four years after treatment35,	 indicating	 MSC	 treatment	 can	 be	 beneficial	 for	
atherosclerotic	patients.





While	 the	 first	 study	 reported	 no	 effect	 on	 serum	 cholesterol	 levels36,	 the	 second	
study	does	not	mention	total	serum	cholesterol	levels.	Lin et al. adoptively	transferred	
human	 MSCs	 into	 ApoE-/-	 mice,	 harboring	 the	 risk	 of	 xenograft	 rejection.	 Wang	
et al.	 used	MSCs	derived	 from	ApoE-/-	mice,	while	we	used	MSCs	 from	a	C57BL/6	















TLR2	 activation	 specifically	 induces	 IL-10	 responses39–41.	 A	 fundamental	 difference	
appears	to	exist	between	different	types	of	antigen	presenting	cells	in	their	capacity	















cells	 to	 reduce	 inflammation.	 One	 of	 the	 most	 investigated	 immune	 cells	 in	 the	
context	of	atherosclerosis	is	the	Treg.	In	earlier	chapters	(chapter	2,	3,	and	4)	our	
treatment	 indirectly	 increased	 Tregs	 and	 this	 contributed	 to	 beneficial	 effects	 on	
atherosclerotic	 lesion	 development.	 However,	 in	 these	 studies	we	 only	 achieved	 a	
modest	 increase	 (1.5-fold	 to	1.8-fold)	and	 these	generally	did	not	 last	 throughout	
the	entire	experiment.	 In	chapter 6,	we	 therefore	assessed	whether	an	 immense	
and	prolonged	increase	in	Tregs,	by	administration	of	an	IL-2/anti-IL2	complex,	could	
reduce	atherosclerotic	lesion	development	and	induce	regression	of	pre-established	
lesions	 in	 parallel	 to	 a	 switch	 to	 a	 normal	 chow	 diet.	 This	 treatment	 resulted	 in	
an	 overall	 10-fold	 induction	 of	 Tregs	 and	 increased	 splenic	 IL-10	 responses.	 Treg	
expansion	 prevented	 atherosclerotic	 lesion	 development	 by	 39%,	 suggesting	 that	
Tregs	can	potently	inhibit	initial	atherosclerosis.	However,	while	Tregs	did	not	affect	
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proteasome	is	required.	Additionally	the	proteasome	plays	a	central	role	 in	several	





dyslipidemia.	 Indeed,	 we	 found	 a	 significant	 reduction	 of	 monocyte/macrophage	


















and	 10%	 neutrophils44.	 Monocytes	 represent	 up	 to	 15%	 of	 circulating	 leukocytes	
in	 humans	 and	 represent	 three	 subsets,	 while	 only	 up	 to	 4%	 are	 found	 in	 mice	



















correlation	 study	 additionally	 found	 that	 murine	 inflammatory	 responses	 mostly	
correlate	with	genomic	 responses	 in	humans53,	 suggesting	 that	mouse	models	are	




















lack	 side-effects.	 For	 MSCs	 it	 has	 been	 established	 in	 clinical	 trials	 that	 they	 can	




in chapter 2 is	translatable	into	the	clinic.	Both	DCs	and	LDL	can	be	isolated	from	
patients	 and	 can	 therefore	 generate	 a	 patient-tailored	 therapy.	 For	 the	 treatment	
of	multiple	sclerosis	a	similar	approach	has	been	used:	coupling	of	antigenic	myelin	
peptides	 to	 apoptotic	 peripheral	 blood	 mononuclear	 cells	 derived	 from	 patients.	
Last	year	a	phase	 I	 clinical	 trial	 showed	 this	approach	 to	be	safe	and	 to	decrease	
antigen-specific	T	cells61.	This	trial	provides	first	evidence	in	men	that	antigen-coupled	
apoptotic	 cells	 results	 in	 antigen-specific	 tolerance.	 In	 graft-versus-host	 disease,	






beneficial	 for	 atherosclerosis	 and	 unstable	 angina,	 but	 could	 also	 prove	 beneficial	
after	MI,	which	results	 in	a	massive	recruitment	of	monocytes	and	a	worsening	of	
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underlying	 atherosclerosis.	 Apoptotic	 cell	 treatment	 could	 reduce	 these	monocyte	
responses	and	simultaneously	stabilize	lesions,	preventing	a	recurrent	event.	However,	
treatment	would	have	 to	be	 immediately	upon	MI	and	could	 therefore	not	 include	
oxLDL	loading	or	DC	culture,	so	here	the	potential	of	extracorporeal	photopheresis	
should	be	explored.
	 In	 atherosclerosis,	 vaccination	 with	 IL-10-treated	 ApoB100-pulsed	
(tolerogenic)	DCs	has	been	shown	to	reduce	lesion	development	in	the	aorta	by	70%,	
due	 to	an	 inhibition	of	T	cell	 responses63.	 In	an	opposite	approach,	our	 laboratory	
has	 shown	 that	 DC	 therapy	 with	 oxLDL-pulsed	 LPS-stimulated	 (mature)	 DCs	 also	
reduced	carotid	artery	lesion	development	induced	by	collar	placement	by	85%.	The	
reduced	 lesion	was	 found	 to	 likely	 result	 from	 the	 induction	 of	 oxLDL-specific	 IgG	






as	 this	 seemed	 a	more	 straightforward	 approach	 to	 reduce	 inflammation.	 Indeed,	
we	show	that	adoptive	transfer	of	tolerogenic	DCs	can	reduce	atherosclerotic	lesions	
providing	further	evidence	that	a	tolerogenic	DC-based	therapy	is	a	feasible	approach	
to	 treat	 atherosclerosis.	 Moreover,	 we	 show	 that	 enhancing	 β-catenin	 signaling	 in	
transferred	DCs	could	increase	their	therapeutic	potential.
	 In	 addition	 to	 DC	 therapies,	 we	 describe	 in	 chapter 4	 that	 MSCs	 can	
significantly	inhibit	atherosclerotic	lesion	development.	Because	MSCs	have	been	found	











cells,	 as	 e.g.	 stabilization	 of	 β-catenin,	will	 enable	 the	 adoptive	 transfer	 of	 potent	
immunoregulators	 that	execute	 targeted	actions	without	undergoing	differentiation	























type	 1	 diabetes70,71.	 The	 potency	 of	 IL-2	was	 found	 to	 be	 increased	 in	 complexes	
with	 IL-2	monoclonal	 antibodies,	which	was	 found	 to	 significantly	 expand	Tregs	 in	
mice	 and	 e.g.	 potently	 reduce	 experimental	 autoimmune	 encephalomyelitis,	 islet	
transplantation	and	asthma72,73.	We	have	shown	that	these	IL-2	complexes	can	also	
reduce	 atherosclerosis	 development	 and	 increase	 stability	 of	 advanced	 lesions	 in	
LDLr-/-,	which	was	later	confirmed	by	another	group	in	ApoE-/- mice74.	Future	studies	
will	 have	 to	 determine	whether	 these	 IL-2	 complexes	 are	 superior	 to	 regular	 IL-2	
administration	in	patients	and	whether	its	administration	is	safe.	IL-2	in	a	combination	
therapy	with	rapamycin	has	also	been	found	to	increase	Tregs	in	patients	with	type	





for	 graft-versus-host	 disease,	 transplantation,	 and	 autoimmunity77.	 Future	 studies	
will	 have	 to	determine	whether	direct	 in	 vivo	expansion	or	 in	 vitro	expansion	and	
subsequent	administration	is	more	beneficial.	An	exciting	challenge	will	also	be	the	
generation	of	antigen-specific	Tregs	for	atherosclerosis	therapy.	Our	 laboratory	has	





targets	 different	 enzymes	 in	 lipogenesis	 than	 statins,	 it	 is	 likely	 that	 combination	
therapies	would	 be	 able	 to	more	 dramatically	 reduce	 cholesterol	 levels.	Moreover,	
Bortezomib	 could	 be	 effective	 in	 patients	 unresponsive	 to	 statin	 treatment.	 In	
addition,	its	anti-inflammatory	effect	could	also	compliment	anti-inflammatory	effects	












found	 to	 have	 extensive	 effects	 on	 atherosclerosis	 (Figure	 2).	 Numerous studies 
have	assessed	the	beneficial	effects	of	IL-10	on	atherosclerosis,	such	as	adenoviral	
gene	 transfer33,83,84,	 transgenic	mice	 expressing	 IL-10	 under	 the	 IL-2	 promoter85,86 
or	 the	 CD68	 promoter87,	 and	 IL-10	 deficient	 C57BL/6	mice85,88	 and	 ApoE-/- mice89.	
Interestingly,	 some	 studies	 found	 that	 IL-10	 reduces	 cholesterol	 levels33,83,	 while	
others	 found	enhanced	cholesterol89,	or	no	effects84,85,88.	 In	general,	 IL-10	potently	
affects	many	inflammatory	processes,	for	example	it	reduces	expression	of	adhesion	
molecules	 on	 endothelial	 cells85,90,	 reduces	CCL2	 levels83,	 inhibits	DC	maturation90,	
affects	monocyte	responses90,	reduces	lesional	macrophages84,	increases	macrophage	





















Inhibition of pro-inflammatory 











Inhibition of monocyte 
recruitment  to lesions
Figure 2. IL-10 affects multiple inflammatory responses in atherosclerosis and has been 

















	 In	 the	 past,	 several	 other	 anti-inflammatory	 strategies	 for	 atherosclerosis	
have	 been	 explored.	 Just	 to	 name	 a	 few:	 subcutaneous	 vaccination	 with	 native	
LDL	 or	 antigenic	 peptides	 from	 LDL92–96,	 intramuscular	 vaccination	 against	 IL-1297,	
immunization	 against	 apoB100-specific	 TCRs98,	 CD40L	 blockade99,100	 and	 OX40L	
blockade101,102	have	all	been	evaluated	in	preclinical	animal	models.	Anti-inflammatory	
approaches	 are	 now	 starting	 to	 be	 validated	 in	 first	 clinical	 trials.	 Currently	 two	
large	 placebo-controlled	 clinical	 trials,	 the	 Cardiovascular	 Inflammation	 Reduction	
Trial	 (CIRT)	 and	 the	Canakinumab	Anti-Inflammatory	Thrombosis	Outcomes	Study	
(CANTOS),	 are	 ongoing	 to	 establish	 whether	 lowering	 inflammation	 will	 reduce	
cardiovascular	events.	The	CIRT	evaluates	the	effect	of	methotrexate103,	which	in	low	
doses	is	anti-inflammatory,	and	the	CANTOS	evaluates	the	effect	of	inhibiting	IL-1β104.	
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interfering	with	inflammatory	pathways	will	reduce	cardiovascular	events.	As	not	all	
patients	 enrolled	 in	 the	 CIRT	 and	CANTOS	 trial	 are	 taking	 statins103,104,114,	 it	 could	
be	interesting	to	determine	if	combination	with	statin	use	is	more	beneficial.	Likely,	
as	 atherosclerosis	 is	 determined	 by	 dyslipidemia	 and	 inflammation,	 the	 future	 of	
cardiovascular	treatment	strategies	will	 lie	 in	a	combination	treatment	for	reducing	





lie	 in	 reducing	 both	 inflammation	 and	 dyslipidemia,	 either	 by	 administering	 drugs	
potently	affecting	both	(such	as	bortezomib),	or	by	combination	therapies.
	 In	 summary,	 our	 studies	 confirm	 that	 immune	 cell	 therapies	 show	 great	
potential	 for	 the	 treatment	 of	 atherosclerosis.	 However,	 several	 challenges	 in	
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vaatlijden	 en	 cerebrovasculaire	 aandoeningen1.	 Atherosclerose	 of	 aderverkalking	
vormt	de	belangrijkste	oorzaak	van	het	ontstaan	van	HVZ.	De	grootste	risicofactoren	
voor	 het	 ontwikkelen	 van	 hart-	 en	 vaatziekten	 zijn	 een	 vetrijk	 dieet,	 te	 weinig	
lichaamsbeweging,	 stress	 en	 overmatig	 alcoholgebruik	 en	 roken1,2.	 Naast deze 








herseninfarcten5,6.	 Helaas	 neemt	 als	 gevolg	 van	 deze	 verbeterde	 behandeling	 het	






een	 enorme	 economische	 impact	 en	 de	 jaarlijkse	 uitgaven	 ten	 gevolge	 van	 HVZ	




operatieve	 behandelingen	 en	 het	 gebruik	 van	 cholesterol	 en	 bloeddrukverlagende	
middelen.
Atherosclerose	 is	 een	 chronische	 autoimmuunachtige	 ziekte	 van	 de	 grote	 en	






De	 huidige	 behandeling	 van	 hart-	 en	 vaatziekten	 is	 voornamelijk	 gericht	 op	 het	
verlagen	van	het	niveau	van	het	slechte	cholesterol,	het	LDL	cholesterol,	in	het	bloed.	
Het	 LDL	 gehalte	 is	 een	 van	 de	 belangrijkste	 risicofactoren	 voor	 atherosclerose	 en	
het	kan	door	gebruik	van	statines	effectief	worden	verlaagd.	Statines	werden	voor	
het	eerst	op	de	markt	gebracht	aan	het	eind	van	de	 jaren	80	van	de	vorige	eeuw	














Het	 doel	 van	 dit	 proefschrift	 was	 om	 nieuwe,	 immunomodulerende	 therapieën	
te	 ontwikkelen	 voor	 atherosclerose.	 Grofweg	 zijn	 er	 twee	methodes	 gebruikt:	 ten	
eerste	een	directe	cellulaire	therapie	en	ten	tweede	het	gebruik	van	geneesmiddelen	
en	 biologics	 om	 de	 immuunrespons	 zodanig	 te	 beïnvloeden	 dat	 atherosclerose	
vermindert.	 Het	 onderzoek	 is	 uitgevoerd	 in	 transgene	 muizen	 die	 doordat	 ze	 de	
receptor	 voor	 het	 slechte	 cholesterol,	 lage	 dichtheidslipoproteïne	 (LDLr),	 	 missen	





(1) Cellulaire therapie: Directe behandeling met (gemodificeerde) 
immuuncellen voor de behandeling van atherosclerose
Het	doel	van	een	anti-inflammatoire	behandeling	voor	atherosclerose	is	het	moduleren	






















Apoptotische	DCs,	 die	werden	 ingespoten	 in	 LDLr-/-	muizen	 in	 een	 initieel	 stadium	
of	 in	een	 later	 stadium	van	atherosclerose,	werden	voornamelijk	opgenomen	door	
DCs	en	macrofagen	in	de	marginale	zone	van	de	milt.	Dit	leidde	tot	de	inductie	van	
een	tolerogeen	fenotype	wat	de	ontwikkeling	van	Tregs	faciliteert.	Daarnaast	vonden	
wij	 dat	 het	 totaal	 aantal	 (inflammatoire)	 monocyten	 werd	 gereduceerd,	 een	 tot	
nu	 toe	onbekend	effect	van	een	behandeling	met	apoptotische	cellen.	Muizen	met	
bestaande	 atherosclerotische	 laesies	 vormen	 een	meer	 relevante	 onderzoekmodel	
omdat	 de	 meeste	 patiënten	 in	 het	 ziekenhuis	 komen	 met	 bestaande,	 meestal	
vergevorderde	stadia	van	atherosclerose.	De	behandeling	van	muizen	met	bestaande	





de	 start	 van	 atherosclerose	 vermindert16.	 Als	 DCs,	 die	 oxLDL	 opnemen	 of	 oxLDL-
geïnduceerde	apoptotische	DCs	dan	wel	macrofagen	(beide	met	een	atherosclerose-




van	 apoptotische	 thymocyten	 de	 ontwikkeling	 van	 atherosclerose	 in	 muizen	
verminderde17.	 Vergelijkbaar	 met	 onze	 studie,	 het	 aantal	 macrofagen	 en	 T	 cellen	
in	de	atherosclerotische	laesies	verminderd.	Opvallend	is	dat	wij	vooral	effecten	op	
monocyten	 hebben	 waargenomen,	 terwijl	 Hosseini	 et al. vooral	 effecten	 op	 de	 B	
cel	 respons	vond,	die	 leidde	tot	een	 inductie	van	IgM-producerende	B1a	cellen	die	
beschermend	zijn	tegen	atherosclerose17.





blootgesteld	 aan	 oxLDL-geïnduceerde	 apoptotische	 DCs,	 de	 expressie	 van	 PD-L1,	
IL-10,	ABCA1	en	ABCG1	werd	verhoogd,	wat	erop	duidt	dat	 liver	X	receptor	(LXR)	
signalering	verhoogd	was	en	dat	 is	 in	 lijn	met	het	 feit	 dat	 zowel	 blootstelling	aan	
apoptotische	cellen	als	aan	cholesterol	LXR	activeert18-20.	Het	is	al	eerder	aangetoond	
dat	de	LXR	activering	in	DCs	resulteert	in	een	tolerogeen	fenotype21.	Onze	hypothese	

















dosis	 PS-liposomen	konden	wij	 echter	 geen	gunstig	 effect	 op	 de	 ontwikkeling	 van	
atherosclerose	in	LDLr-/-	muizen	aantonen.
Een	 toename	 in	 de	 β-catenine	 signalering	 in	 DCs	 is	 een	 andere	 benadering	 om	





signalering	 in	 DCs	 is	 een	 belangrijke	 factor	 in	 het	 ontstaan	 van	 een	 tolerogeen	








CD11c	 expressie	 ook	 in	monocyten	 en	macrofagen	onder	 hypercholesterolemische	
condities	wordt	geïnduceerd29,30.	Interessant	is	dat	Wnt3a	signalering,	wat	β-catenine	







In	 de	 afgelopen	 jaren	 is	 de	 interesse	 in	 de	 mogelijkheden	 en	 voordelen	 van	





dat	 MSCs	 ook	 immuun	 regulerende	 capaciteiten	 hebben	 en	 een	 positief	 effect	 op	



























door	 verhoging	 van	 eNOS	 expressie	 in	 endotheelcellen	 leidend	 tot	 een	 kleinere	
atherosclerotische	 laesie	 in	de	aorta	van	ApoE-/- muizen46.	Een	studie	van	Wang	et 
al.	 beschrijft	 dat	 MSC	 therapie	 de	 atherosclerotische	 laesies	 in	 de	 aortawortel	 in	
ApoE-/-	muizen	verkleint	door	het	induceren	van	Tregs47.	Interessant	is	dat	het	eerste	
onderzoek	geen	effect	op	plasma	cholesterolniveaus	vindt46,	terwijl	de	tweede	studie	









(2) Geneesmiddelen en biologics om de immuuncel functie in vivo te 
moduleren
Naast	 cellulaire	 therapie	 kunnen	 geneesmiddelen	 (small	 molecules)	 en	 biologics	
worden	gebruikt	om	 immuun	cellen	 te	moduleren	of	een	 specifieke	 subset	van	de	
immuun	cellen	te	induceren.




verminderen	 tijdens	het	 opruimen	van	een	pathogeen,	dit	 gebeurt	 om	het	herstel	
van	 de	 weefselhomeostase	 te	 waarborgen.	 De	 activatie	 van	 Toll-Like	 Receptoren	
(TLRs)	 door	 pathogenen	 leidt	 dus	 niet	 alleen	 tot	 initiële	 ontstekingsreacties,	maar	





in	DCs	tot	veel	 lagere	hoeveelheden	IL-10	 leidt50,52.	 In	hoofdstuk 5	 laten	wij	zien	














Er	 zijn	 verschillende	 strategieën	 beschreven	 die	 de	 ontsteking	 verminderen	 door	
immunoregulatoire	of	tolerogene	cellen	te	induceren.	Eén	van	de	meest	onderzochte	
immuuncellen	 in	het	kader	van	atherosclerose	 is	de	Treg.	In	eerdere	hoofdstukken	
(hoofdstukken	 2,	 3	 en	 4)	 verhoogden	 onze	 behandelwijzen	 indirect	 het	 niveau	
van	de	Tregs	en	dit	 droeg	bij	 aan	het	positieve	effect	 van	deze	behandelingen	op	








































echter	wel	 een	 lagere	expressie	van	HMG-CoA	 reductase	 in	de	aorta,	maar	geven	
geen	data	over	de	expressie	in	de	lever.	Waarschijnlijk	is	de	dosis	van	Bortezomib	die	




Het	 zal	 interessant	 zijn	 om	 de	 resultaten	 van	 grote	 klinische	 trials	 zoals	 de	 CIRT	




voor	 de	 patiënt.	 Het	 lijkt	 ook	 waarschijnlijk	 dat	 de	 toekomstige	 cardiovasculaire	
behandelingsstrategie	 juist	 een	 gecombineerde	 behandeling	 voor	 het	 verminderen	
van	 lipiden	 en	 ontsteking	 zal	 zijn,	 aangezien	 atherosclerose	 wordt	 bepaald	 door	





cardiovasculaire	 behandelingsstrategieën	 gericht	 zijn	 op	 het	 reduceren	 van	 zowel	
197
Dutch Summary









1.	 Go,	A.	S.	et al. Heart	disease	and	stroke	statistics--2014	update:	a	report	from	the	American	
Heart	Association.	Circulation	129,	e28–e292	(2014).
2.	 Conen,	 D.	 Alcohol	 consumption	 and	 incident	 cardiovascular	 disease:	 not	 just	 one	 unifying	
hypothesis.	Eur. Heart J. (2015).
3.	 Legein,	B.,	Temmerman,	L.,	Biessen,	E.	A.	L.	&	Lutgens,	E.	Inflammation	and	immune	system	
interactions	in	atherosclerosis.	Cell. Mol. Life Sci. 70,	3847–69	(2013).
4.	 Nicholas,	M.,	Townsend,	N.,	Scarborough,	P.	&	Rayner,	M.	Cardiovascular	disease	in	Europe	2014:	






7.	 Finucane,	M.	M.	 et al. National,	 regional,	 and	 global	 trends	 in	 body-mass	 index	 since	 1980:	
systematic	analysis	of	health	examination	surveys	and	epidemiological	studies	with	960	country-
years	and	9·1	million	participants.	Lancet	377,	557–67	(2011).
8.	 Danaei,	G.	et al. National,	 regional,	and	global	 trends	 in	 fasting	plasma	glucose	and	diabetes	
prevalence	since	1980:	systematic	analysis	of	health	examination	surveys	and	epidemiological	
studies	with	370	country-years	and	2·7	million	participants.	Lancet	378,	31–40	(2011).
9.	 Finegold,	 J.	 A.,	 Asaria,	 P.	&	 Francis,	D.	 P.	Mortality	 from	 ischaemic	heart	 disease	by	 country,	
region,	and	age:	statistics	from	World	Health	Organisation	and	United	Nations.	Int. J. Cardiol. 
168,	934–45	(2013).
10.	 Leal,	 J.,	 Luengo-Fernández,	 R.,	 Gray,	 A.,	 Petersen,	 S.	 &	 Rayner,	 M.	 Economic	 burden	 of	
cardiovascular	diseases	in	the	enlarged	European	Union.	Eur.	Heart	J.	27,	1610–9	(2006).
11.	 Stary,	H.	C.	Lipid	and	macrophage	accumulations	in	arteries	of	children	and	the	development	of	
atherosclerosis.	Am. J. Clin. Nutr.	72,	1297S–1306S	(2000).
12.	 Cannon,	C.	P.	et al.	Intensive	versus	moderate	lipid	lowering	with	statins	after	acute	coronary	




Atherosclerosis.	Arterioscler. Thromb. Vasc. Biol.	33,	2558–65	(2013).
15.	 Elliott,	M.	R.	&	Ravichandran,	K.	S.	Clearance	of	apoptotic	cells:	implications	in	health	and	disease.	
J. Cell Biol.	189,	1059–70	(2010).
16.	 Habets,	K.	L.	L.	et al. Vaccination	using	oxidized	 low-density	 lipoprotein-pulsed	dendritic	cells	
reduces	atherosclerosis	in	LDL	receptor-deficient	mice.	Cardiovasc. Res.	85,	622–30	(2010).
17.	 Hosseini,	H. et al. Phosphatidylserine	Liposomes	Mimic	Apoptotic	Cells	to	Attenuate	Atherosclerosis	
by	Expanding	Polyreactive	IgM	Producing	B1a	lymphocytes.	Cardiovasc. Res. (2015).	doi:10.1093/
cvr/cvv037
18.	 Shiffman,	D.	et al. Large	scale	gene	expression	analysis	of	cholesterol-loaded	macrophages.	J. 
Biol. Chem.	275,	37324–32	(2000).
19.	 Kiss,	R.	S.,	Elliott,	M.	R.,	Ma,	Z.,	Marcel,	Y.	L.	&	Ravichandran,	K.	S.	Apoptotic	cells	 induce	a	










23.	 Fadok,	 V.	 A.	 et al. Exposure	 of	 phosphatidylserine	 on	 the	 surface	 of	 apoptotic	 lymphocytes	
triggers	specific	recognition	and	removal	by	macrophages.	J.	Immunol.	148,	2207–16	(1992).
24.	 Fadok,	V.	A.	et al. A	receptor	for	phosphatidylserine-specific	clearance	of	apoptotic	cells.	Nature 
405,	85–90	(2000).
25.	 Harel-Adar,	 T.	 et al. Modulation	 of	 cardiac	 macrophages	 by	 phosphatidylserine-presenting	





28.	 Manicassamy,	S.	et al.	Activation	of	beta-catenin	 in	dendritic	 cells	 regulates	 immunity	versus	
tolerance	in	the	intestine.	Science	329,	849–53	(2010).
29.	 Geissmann,	F.,	Gordon,	S.,	Hume,	D.	A.,	Mowat,	A.	M.	&	Randolph,	G.	J.	Unravelling	mononuclear	
phagocyte	heterogeneity.	Nat. Rev. Immunol. 10,	453–60	(2010).
30.	 Wu,	 H.	 et al. Functional	 role	 of	 CD11c+	 monocytes	 in	 atherogenesis	 associated	 with	
hypercholesterolemia.	Circulation	119,	2708–17	(2009).
31.	 Schaale,	K.,	Neumann,	J.,	Schneider,	D.,	Ehlers,	S.	&	Reiling,	N.	Wnt	signaling	in	macrophages:	




future.	Clin. Exp. Vaccine Res. 3,	113–6	(2014).
34.	 Keramaris,	N.	C. et al.	Endothelial	progenitor	cells	(EPCs)	and	mesenchymal	stem	cells	(MSCs)	in	
bone	healing. Curr. Stem Cell Res. Ther.	7,	293–301	(2012).
35.	 Glavaski-Joksimovic,	 A.	 &	 Bohn,	 M.	 C.	 Mesenchymal	 stem	 cells	 and	 neuroregeneration	 in	
Parkinson’s	disease.	Exp. Neurol.	247,	25–38	(2013).
36.	 Wen,	 Z.,	 Zheng,	 S.,	 Zhou,	 C.,	 Wang,	 J.	 &	 Wang,	 T.	 Repair	 mechanisms	 of	 bone	 marrow	




bone	marrow	mesenchymal	 stem	 cells	 prevents	 tissue	 damage	 in	 collagen-induced	 arthritis.	
Arthritis Rheum.	56,	1175–86	(2007).




Type	2	Diabetes.	Stem Cells Transl. Med.	1,	125–135	(2012).
41.	 Le	Blanc,	K.	et al.	Mesenchymal	stem	cells	for	treatment	of	steroid-resistant,	severe,	acute	graft-
versus-host	disease:	a	phase	II	study.	Lancet	371,	1579–86	(2008).
42.	 Bai,	 L.	et al. Hepatocyte	growth	 factor	mediates	mesenchymal	 stem	cell–induced	 recovery	 in	
multiple	sclerosis	models.	Nat. Neurosci. 15,	862–70	(2012).
43.	 Von	Der	 Thüsen,	 J.	H.	et al.	 Attenuation	 of	 atherogenesis	 by	 systemic	 and	 local	 adenovirus-
mediated	gene	transfer	of	interleukin-10	in	LDLr-/-	mice.	FASEB	J.	15,	2730–2	(2001).
44.	 Ruan,	H.	et al. Profiling	gene	transcription	in	vivo	reveals	adipose	tissue	as	an	immediate	target	
of	tumor	necrosis	factor-alpha:	implications	for	insulin	resistance.	Diabetes	51,	3176–88	(2002).
45.	 Benedek,	I.,	Bucur,	O.	&	Benedek,	T.	Intracoronary	infusion	of	mononuclear	bone	marrow-derived	
stem	cells	is	associated	with	a	lower	plaque	burden	after	four	years.	J. Atheroscler. Thromb. 21,	
217–29	(2014).
46.	 Lin,	Y.-L.,	Yet,	S.-F.,	Hsu,	Y.-T.,	Wang,	G.-J.	&	Hung,	S.-C.	Mesenchymal	Stem	Cells	Ameliorate	
Atherosclerotic	 Lesions	 via	 Restoring	 Endothelial	 Function.	Stem Cells Transl. Med. 4,	 44–55	
(2014).
47.	 Wang,	Z.	X.	et al. Mesenchymal	 stem	cells	alleviate	atherosclerosis	by	elevating	number	and	
function	of	CD4+CD25+FOXP3+	regulatory	T-cells	and	inhibiting	macrophage	foam	cell	formation.	
Mol. Cell. Biochem. 400,	163–172	(2014).
48.	 Westerterp,	M. et al. ATP-binding	cassette	transporters,	atherosclerosis,	and	inflammation.	Circ. 
Res.	114,	157–70	(2014).
49.	 Saraiva,	M.	&	O’Garra,	A.	The	regulation	of	IL-10	production	by	immune	cells.	Nat. Rev. Immunol. 
10,	170–81	(2010).
50.	 Frodermann,	 V.	 et al. A	 modulatory	 interleukin-10	 response	 to	 staphylococcal	 peptidoglycan	




51.	 Netea,	M.	G.	et al. Toll-like	receptor	2	suppresses	 immunity	against	Candida	albicans	through	
induction	of	IL-10	and	regulatory	T	cells.	J. Immunol. 172,	3712–8	(2004).
52.	 Boonstra,	A.	et al. Macrophages	and	myeloid	dendritic	cells,	but	not	plasmacytoid	dendritic	cells,	
produce	 IL-10	 in	 response	 to	MyD88-	and	TRIF-dependent	 TLR	 signals,	 and	TLR-independent	
signals.	J. Immunol. 177,	7551–8	(2006).
53.	 Wilck,	N.	et al. Attenuation	of	early	atherogenesis	 in	 low-density	lipoprotein	receptor-deficient	























effect of Staphylococcus aureus	cell	wall	components	on	human	innate	immune	cells	
and	effects	on	ensuing	adaptive	immune	responses,	which	resulted	in	a	publication	
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ABCA1	 	 	 ATP-Binding	Cassette	transporter	A1
ABCG1	 	 	 ATP-Binding	Casette	transporter	G1
ACAT	 	 	 Acyl-CoA	cholesterol	ester	Transferase
AP-1	 	 	 Activating	Protein-1	
APC	 	 	 Antigen-Presenting	Cell
ApoA-I	 	 	 Apolipoprotein	A-I
ApoB-100		 	 Apolipoprotein	B100
ApoE	 	 	 Apolipoprotein	E
apopctrl-DCs	 	 Unpulsed	control	apoptotic	dendritic	cells
apopox-DCs		 	 OxLDL-induced	apoptotic	dendritic	cells
BM	 	 	 Bone	Marrow
BMT	 	 	 Bone	Marrow	Transplantation
CANTOS	 	 	 Canakinumab	Anti-Inflammatory	Thrombosis	Outcomes	Study
CCL	 	 	 CC	chemokine	Ligand
CCR	 	 	 CC	chemokine	Receptor
CD	 	 	 Cluster	of	Differentiation
cDC	 	 	 conventional	Dendritic	Cell
CD11c-βcatEX3	DCs		 DCs	with	constitutive	β-catenin	signaling
CFSE	 	 	 CarboxyFluorescein	diacetate	Succinimidyl	Ester
CIRT	 	 	 Cardiovascular	Inflammation	Reduction	Trial
CLR	 	 	 C-type	lecin	receptor
CMP	 	 	 common	myeloid	progenitor
CRP	 	 	 C-Reactive	Protein
CTLA-4	 	 	 Cytotoxic	T	Lymphocyte	Antigen-4
CVD	 	 	 CardioVascular	Disease
CX3CL	 	 	 CX3C	chemokine	Ligand
CX3CR	 	 	 CX3C	chemokine	Receptor
CXCL	 	 	 CXC	chemokine	Ligand
CXCR	 	 	 CXC	chemokine	Receptor
DAMP	 	 	 Danger-Associated	Molecular	Pattern
DC	 	 	 Dendritic	Cell
DGAT	 	 	 DiGlyceride	AcylTransferase
DMEM	 	 	 Dulbecco’s	Modified	Eagle’s	Medium
DMSO	 	 	 Dimethylsulfoxide
DNA	 	 	 Deoxyribo	Nucleic	Acid
DTR	 	 	 Diphtheria	Toxin	Receptor
EC	 	 	 Endothelial	Cell
ELISA	 	 	 Enzyme-Linked	ImmunoSorbent	Assay
eNOS	 	 	 Endothelial	cell	Nitric	Oxide	Synthase
ERK	 	 	 Extracellular	signal-Regulated	Kinase
FACS	 	 	 Fluorescence	Activated	Cell	Sorting
FAS	 	 	 Fatty	Acid	Synthase
FDA	 	 	 United	States	Food	and	Drug	Administration
FITC	 	 	 Fluorescein	IsoThioCyanate
Foxp3	 	 	 Forkhead	box	p3
GAPDH	 	 	 GlycerAldehyde-3-Phosphate	DeHydrogenase
GM-CSF	 	 	 Granulocyte-Macrophage	Colony-Stimulating	Factor
HDL	 	 	 High-Density	Lipoprotein
HIV	 	 	 Human	Immunodeficiency	virus
HK-SA	 	 	 Heat-Killed	Staphylococcus aureus
HMG	 	 	 3-Hydroxy-3-Methyl-Glutaryl
hLN	 	 	 Draining	Lymph	Node	of	the	heart
HO-1	 	 	 Heme	Oxygenase-1
HPRT	 	 	 Hypoxanthine	PhosphoRibosyl	Transferase
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Abbreviations
HSP	 	 	 Heat	shock	protein
HSPC	 	 	 Hematopoietic	Stem	and	Progenitor	Cells
ICAM-1	 	 	 IntraCellular	Adhesion	Molecule-1
IDO	 	 	 Indoleamine-2,3-DiOxygenase
IFN-γ	 	 	 Interferon	γ
Ig	 	 	 Immunoglobulin
IL	 	 	 Interleukin
iNOS	 	 	 Inducible	Nitric	Oxide	Synthase
i.p.	 	 	 Intraperitoneal
iPS	 	 	 induced	Pluripotent	Stem	cells
i.v.	 	 	 Intravenous
LCAT	 	 	 Lecithin	Cholesterol	AcylTransferase
LDL	 	 	 Low-Density	Lipoprotein
LDLr	 	 	 Low-Density	Lipoprotein	receptor
LN	 	 	 lymph	node
LPL	 	 	 LipoProtein	Lipase
LPS	 	 	 LipoPolySaccharide
LRP1	 	 	 Low	density	lipoprotein	receptor-related	protein	1
LXR	 	 	 Liver	X	Receptor
MAL	 	 	 MyD88	adaptor-like	protein	
MAPK	 	 	 Mitogen-Activated	Protein	Kinase
M-CSF	 	 	 Macrophage	Colony	Stimulating	Factor
MDA-LDL	 	 	 Malondialdehyde-modified	Low-Density	Lipoprotein
MDP	 	 	 macrophage	DC	progenitor
MHC	 	 	 Major	Histocompatibility	Complex
MI	 	 	 Myocardial	Infarction
miRNA	 	 	 micro-RiboNucleic	Acid
MMP	 	 	 Matrix	MetalloProteinase
moDC	 	 	 monocyte-derived	Dendritic	Cell
Mreg	 	 	 Regulatory	Macrophages
mRNA	 	 	 messenger	RiboNucleic	Acid
MS	 	 	 Multiple	Sclerosis
MSC	 	 	 Mesenchymal	Stem	Cell
MTTP	 	 	 Microsomal	Triglyceride	Transfer	Protein
MyD88	 	 	 Myeloid	Differentiation	primary-response	protein	88
NADPH	 	 	 Nicotinamide	Adenine	Dinucleotide	PHosphate
NK(T)	 	 	 Natural	Killer	(T)	Cells
oxLDL		 	 	 Oxidized	low-density	lipoprotein
OxPAPC	 	 	 oxidized	1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine
p53	 	 	 Protein	53
PAMP	 	 	 Pathogen-Associated	Molecular	Pattern
pDC	 	 	 plasmacytoid	Dendritic	Cell
PE	 	 	 Phycoerythrin
PerCP	 	 	 Peridinin	Chlorophyll-A	Protein
PD-L1	 	 	 Programmed	Death-Ligand	1
PI	 	 	 Propidium	Iodide
PI3K	 	 	 Phosphoinositide	3-Kinase
PPARγ	 	 	 Peroxisome	Proliferator-Activated	Receptor	γ
PRR	 	 	 Pattern	Recognition	Receptor
PS	 	 	 PhosphatidylSerine
qPCR	 	 	 quantitative	Polymerase	Chain	Reaction
respDC	 	 	 responder	DC
RNA	 	 	 RiboNucleic	Acid
Rpl27	 	 	 60S	ribosomal	protein	L27
RXR	 	 	 Retinoid	X	Receptor
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Abbreviations
Scd1		 	 	 Stearoyl-CoA	Desaturase-1
SCF	 	 	 Stem	Cell	Factor
SCID	 	 	 Severe	Combined	Immunodeficiency
SDF-1	 	 	 Stromal	cell	Derived	Factor-1
SEM	 	 	 Standard	Error	of	the	Mean
siRNA	 	 	 Small	interfering	RiboNucleic	Acid
SMC	 	 	 Smooth	Muscle	Cell
SNP	 	 	 Single	Nucleotide	Polymorphisms
SOCS	 	 	 Suppressor	Of	Cytokine	Signaling
SR-A	 	 	 Scavenger	Receptor	A
SR-BI	 	 	 Scavenger	Receptor	BI
SREBP-1c		 	 Sterol	Regulatory	Element-Binding	Protein	1
STAT	 	 	 Signal	Transducer	and	Activator	of	Transcription
TAM	 	 	 Tumor-Associated	Macrophages
TCR	 	 	 T	Cell	Receptor
TG	 	 	 TriGlycerides
TGF-β   Transforming	Growth	Factor-β
Th	 	 	 T	helper
TLR	 	 	 Toll-like	Receptor
TNF-α	 	 	 Tumor	Necrosis	Factor-α
Treg	 	 	 regulatory	T	cell
TRAIL	 	 	 Tumor	necrosis	factor-Related	Apoptosis-Inducing	Ligand
TRIF	 	 	 TIR	domain-containing	adaptor	protein	inducing	IFNβ
VCAM-1	 	 	 Vascular	Cell	Adhesion	Molecule-1
VEGF	 	 	 Vascular	Endothelial	Growth	Factor
VLDL	 	 	 Very	Low-Density	Lipoprotein
VSMC	 	 	 Vascular	Smooth	Muscle	Cell
WT	 	 	 Wild	Type
WTD	 	 	 Western-type	diet
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